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ABSTRACT
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder whose
etiology is unknown. Recent studies have implicated alterations in calcium homeostasis
as a pathogenic contributor to AD. Calcium dysregulation has been observed in aged and
AD brains, an event which could potentially facilitate the development of multiple
pathologies observed in AD. Specifically, disrupting intracellular calcium levels in vitro
has been demonstrated to increase amyloid-beta (Aβ) production, tau phosphorylation,
and neuronal loss. However, there is a paucity of data on the behavioral and biochemical
consequences of chronic in vivo perturbation of calcium homeostasis. In a series of
experiments designed to evaluate the effects of chronic calcium dysregulation, we
chronically administered different dosages of ryanodine or thapsigargin directly into the
lateral ventricles at a minimal flow rate via Alzet osmotic minipumps. To investigate
interactions with neuroinflammation, a common occurrence in AD, experiment 3
examined the effects of an acute inflammatory response on chronic calcium
dysregulation. Learning and memory was examined in multiple paradigms including the
Morris water maze and novel object recognition. Results indicate chronic alterations in
calcium regulation produced deficits in the water maze and novel object recognition task
following six weeks of central infusion. Analyses of protein levels revealed that there
may be neurochemical changes consistent with AD following chronic calcium
dysregulation. The induction of neuroinflammation combined with calcium dysregulation
produced similar deficits. The data suggest that altered neural calcium handling may play
a significant role in AD. Additionally, these data may shed light on the role of calcium
regulation in learning and memory.
iii

TABLE OF CONTENTS
ABSTRACT....................................................................................................................... iii
LIST OF TABLES .............................................................................................................. v
LIST OF FIGURES ........................................................................................................... vi
CHAPTER 1 INTRODUCTION ................................................................................... 1
Experimental Rationale ............................................................................................... 5
CHAPTER 2 REVIEW OF RELATED LITERATURE ............................................... 7
Amyloid β Hypothesis ................................................................................................ 7
Tau Hypothesis ......................................................................................................... 15
Cholinergic Hypothesis............................................................................................. 19
Neuroinflammatory Hypothesis ................................................................................ 22
Calcium Hypothesis .................................................................................................. 23
Experiments and Hypotheses .................................................................................... 31
CHAPTER 3 MATERIALS AND METHODS .......................................................... 36
Subjects ..................................................................................................................... 36
Surgery ...................................................................................................................... 36
Drug Treatments ....................................................................................................... 37
Behavioral Testing .................................................................................................... 38
Temperature and Weight Tracking ........................................................................... 39
Open Field and Novel Object Recognition ............................................................... 39
Morris Water Maze ................................................................................................... 40
Tissue Collection ...................................................................................................... 42
SDS/PAGE (Western Blots) ..................................................................................... 43
Statistical Analyses ................................................................................................... 44
CHAPTER 4 RESULTS .............................................................................................. 46
Experiment 1 ............................................................................................................. 46
Experiment 2 ............................................................................................................. 59
Experiment 3 ............................................................................................................. 66
CHAPTER 5 DISCUSSION ........................................................................................ 85
Conclusions ............................................................................................................... 95
BIBLIOGRAPHY ............................................................................................................. 98
VITA ............................................................................................................................... 117

iv

LIST OF TABLES
Table 1
Table 2
Table 3
Table 4
Table 5
Table 6

Outline of the groups for each experiment with drug dosages ...................38
Western blot data from hippocampus in experiment 1
of Aβ oligomers with β-actin as a loading control.....................................53
Western blot data from cortex in experiment 1
of Aβ oligomers with β-actin as a loading control.....................................57
Western blot data from experiment 2
of Aβ oligomers with β-actin as a loading control.....................................66
Western blot data from hippocampus in experiment 3
of Aβ oligomers with β-actin as a loading control.....................................77
Western blot data from cortex in experiment 3
of Aβ oligomers with β-actin as a loading control.....................................82

v

LIST OF FIGURES
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Figure 11
Figure 12
Figure 13
Figure 14
Figure 15
Figure 16
Figure 17
Figure 18
Figure 19
Figure 20
Figure 21
Figure 22
Figure 23
Figure 24
Figure 25
Figure 26
Figure 27
Figure 28
Figure 29
Figure 30
Figure 31
Figure 32
Figure 33
Figure 34
Figure 35
Figure 36

Timeline of experimental manipulations and testing ................................39
Open field testing in experiment 1 ............................................................46
NOR testing in experiment 1 .....................................................................48
MWM testing in experiment 1 ..................................................................49
MWM probe trial performance in experiment 1 .......................................51
Oligomeric Aβ protein levels in hippocampus from experiment 1 ...........52
Correlations between probe trial performance and hippocampal oAβ levels
in experiment 1 ..........................................................................................54
Ptau protein levels in hippocampus from experiment 1 ............................55
CB-D28k protein levels in hippocampus from experiment 1 ....................56
Oligomeric Aβ protein levels in cortex from experiment 1 ......................56
Correlations between probe trial performance and cortical oAβ levels in
experiment 1...............................................................................................58
Ptau protein levels in cortex from experiment 1 .......................................58
CB-D28k protein levels in cortex from experiment 1 ...............................59
Open field testing in experiment 2 ............................................................60
NOR testing in experiment 2 .....................................................................61
MWM testing in experiment 2 ..................................................................62
MWM probe trial performance in experiment 2 .......................................64
Oligomeric Aβ protein levels in hippocampus from experiment 2 ...........65
Ptau protein levels in hippocampus from experiment 2 ............................67
CB-D28k protein levels in hippocampus from experiment 2 ....................68
Temperature data at baseline and at multiple time points following LPS or
saline injections..........................................................................................69
Analysis of weights at baseline and at multiple time points following LPS
or saline injections .....................................................................................70
Open field testing in experiment 3 ............................................................71
NOR testing in experiment 3 .....................................................................72
MWM testing in experiment 3 ..................................................................73
MWM probe trial performance in experiment 3 .......................................75
Oligomeric Aβ protein levels in hippocampus from experiment 3 ...........76
Correlations between probe trial performance and hippocampal oAβ levels
in experiment 3 ..........................................................................................78
Correlations between thap+LPS group probe trial performance and
hippocampal oAβ levels from experiment 3 ..............................................79
Ptau protein levels in hippocampus from experiment 3 ............................79
Tau protein levels in hippocampus from experiment 3 .............................80
CB-D28k protein levels in hippocampus from experiment 3 ....................81
Oligomeric Aβ protein levels in cortex from experiment 3 ......................81
Ptau protein levels in cortex from experiment 3 .......................................83
CB-D28k protein levels in cortex from experiment 3 ...............................83
Correlations between thap+LPS group probe trial performance and
cortical CB-D28k levels from experiment 3 ..............................................84

vi

CHAPTER 1
INTRODUCTION
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by a
progressive loss of memory and a decline in cognitive function (Heese & Akatsu, 2006).
It is the most common cause of age-related dementia accounting for 50-60% of agerelated cases. The average age of onset for AD is 65 years, while most cases occurring
before this age are referred to as early-onset familial AD, with identifiable genetic links.
Dementia includes the aforementioned memory loss, confusion, disorientation, anxiety,
delusions and apathy or depression (Terry & Katzman, 1983). As the disease advances,
symptoms may include anger, aggression, language problems, impaired motor function,
and psychoses (Souren et al., 1995; Waldemar et al., 2007).
In addition to the behavioral disruptions associated with AD, several pathological
changes have been observed in the brain including amyloid-beta (Aβ) plaque deposition,
neurofibrillary tangle formation, and the progressive loss of synapses and neurons, most
notably cholinergic neurons (Arriagada et al., 1992; Bartus et al., 1982; Glenner & Wong,
1984; Grundke-Iqbal et al., 1986; Masters et al., 1985; Terry et al., 1991). These
pathological changes are the hallmarks of the disease, and may be responsible for the
cognitive and behavioral deficits exhibited in AD. However, no current widely accepted
theory exists that is able to account for all the pathological changes observed. Mounting
evidence suggests calcium dysregulation may play a pivotal role in AD and may
represent a unifying, causative factor in the disorder.
One of the most extensively investigated hallmarks of the disorder is the senile
plaques observed in post-mortem examinations. Aβ proteins form the core of senile
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plaques, one of the pathological changes which may be inducing the neuronal loss seen in
AD (Glenner & Wong, 1984; Masters et al., 1985). Senile plaques are extracellular
structures composed mainly of aggregated Aβ, an endogenous protein of unknown
function, and they are found almost exclusively in AD and AD-related pathologies like
Down syndrome (Wisniewski et al., 1985). Several studies suggest that the accumulation
of Aβ in the brain may initiate or lead to the pathogenesis of AD (reviewed in Selkoe,
2001). These findings and others have led to the amyloid cascade hypothesis (Hardy &
Higgins, 1992), which suggests that the amyloid deposits that form plaques are the
causative event in AD and the resulting neurodegeneration is a by-product of this
buildup. Evidence supporting this hypothesis comes from genetic studies showing
mutations in the genes associated with familial and late-onset AD lead to increased Aβ
aggregation and cognitive deficits (Corder et al., 1993; Goate et al., 1991; Levy-Lahad et
al., 1995; Murrell et al., 1991; Sherrington et al., 1995).
Investigators have been searching for genetic ties to AD for years in an attempt to
determine the etiology of the disease but with only mild success. Although a few genes
have been implicated as risk factors, none have yet provided a clear link between the
pathogenesis of sporadic AD and specific genetic targets, with most promising targets
tied to familial AD. Mutations in the amyloid precursor protein (APP), which is
responsible for the formation of Aβ peptides and whose encoding gene is located on
chromosome 21, have been linked to early-onset familial AD (Goate et al., 1991; Murrell
et al., 1991). Interestingly, patients with Down syndrome, a trisomy (additional copy) of
chromosome 21, show AD pathology by 40 years of age (Holtzman et al., 1996).
Alternative genetic approaches have implicated mutations in genes called presenilins (PS)
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which have also been tied to early-onset AD, specifically presenilin-1 (PS-1) and
presenilin-2 (PS-2) located on chromosomes 14 and 1, respectively (Levy-Lahad et al.,
1995; Sherrington et al., 1995). In sporadic AD, genetic investigations have implicated a
specific allele of Apolipoprotein E (ApoE), whose gene is localized on chromosome 19,
which has been linked to an increased likelihood of developing the disease (Corder et al.,
1993). This risk factor is not linked to a mutation, but the inheritance of specific alleles.
Although genetic linkage studies have provided useful insight into potential AD etiology,
genetic mutations (i.e. APP or PS) related to Aβ can only account for a very small
percentage of AD cases. A further limitation of the Aβ hypothesis is that many studies
have indicated that there is a weak correlation between the number or size of amyloid
deposits and the severity of the dementia, and that other pathologies seem to correlate
better with the memory loss seen in AD (Arriagada et al., 1992; Snowdon et al., 1997;
Terry et al., 1991). Therefore, additional pathologies such as the hyperphosphorylation of
tau have been the focus of much research.
Neurofibrillary tangles (NFTs) are another neuropathological hallmark of AD and
are composed mainly of hyperphosphorylated tau, a protein that is associated with
microtubule stability and assembly. Tau hyperphosphorylation leads to the formation of
paired helical filaments (PHF) which are thought to lead to microtubule disintegration
and neuron death (Goedert, 1996). Because the amount of neurofibrillary tangles
correlates positively with the severity of dementia in AD (Arriagada et al., 1992), it is of
great interest to investigators of the disorder and those developing pharmacological
treatments. In addition, the regions of the brain that appear to undergo the greatest
degeneration of neurons and synapses in AD are those that project to or from areas that
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have high densities of plaques and tangles, specifically the hippocampus, neocortex, and
basal forebrain (for review, see Kar et al., 2004). The latter region contains large numbers
of cholinergic neurons which project to the hippocampus and cortex. Acetylcholine
(ACh), principally an excitatory neurotransmitter, is important for attentional processes,
as well as learning and memory (Deutsch, 1971; Wenk et al., 1994; Woolf, 1996). A
reduction in neurons containing ACh has been consistently observed in AD, particularly
in the early stages of the disorder.
Cholinergic cell loss is a hallmark of the neurodegeneration in AD, marked by a
progressive loss of ACh-containing neurons with a corresponding decline in cognitive
function (Perry et al., 1981; Terry et al., 1991). The cholinergic hypothesis of AD
postulates that the cognitive deficits in AD are caused by the early loss of cholinergic
basal forebrain (CBF) neurons (Bartus et al., 1982). This hypothesis is supported by
many post-mortem studies which demonstrate that the loss of CBF neurons occurs early
in the disease progression, likely before a clinical diagnosis is reached (Bartus et al.,
1982; Beach et al., 1997, 2000; Bowen et al., 1982). Also, the severity of the dementia in
AD is highly correlated with the amount of cholinergic loss (Perry et al., 1981). Although
CBF neurons are associated with early degeneration in AD, the pervasive nature of the
cell loss throughout the course of the disorder suggests alternative mechanisms may be
responsible because these cholinergic neurons are specifically localized. One such
mechanism is the dysregulation of intracellular calcium, a progressive event which may
account for the widespread neurodegeneration and neuropathologies in AD.
The activity of calcium ions is essential for a number of neuronal processes
including transmitter release, transcriptional regulation, synaptic plasticity, and many
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others (Bading et al., 1993; Borst & Sakmann, 1996; Greer & Greenberg, 2008;
Hardingham et al., 1997). Many cellular resources are devoted to tightly regulating
intracellular calcium levels such as calcium pumps, transporters, exchangers, and
channels. The proper functioning of this machinery is necessary for maintaining calcium
homeostasis and normal cellular function. Any perturbation of the mechanisms
responsible for regulating calcium levels may have deleterious consequences and
potentially play a role in disorders.
The calcium hypothesis of aging and neurodegenerative disease was first
proposed in the 1980s (Gibson & Peterson, 1987; Khachaturian, 1987; Landfield, 1987;
Landfield et al., 1989), suggesting that sustained intracellular calcium disruptions may be
the cause of age-related disorders, including AD. More recently, increasing lines of
evidence point to disrupted calcium homeostasis as a causative factor in AD
(Bezprozvanny & Mattson, 2008; Bojarski et al., 2008; Camandola & Mattson, 2011;
Thibault et al., 2007; Thibault & Landfield, 1996). Calcium dysregulation has been
implicated in several pathologies of AD including Aβ and tau aggregation, and neuronal
loss. Each of these pathologies has also been implicated in the cognitive impairments in
AD (Arriagada et al., 1992; Cleary et al., 2005; Hsiao et al., 1996; Terry et al., 1991). In
the experiments outlined below, we will examine the effects of altering intracellular
calcium levels on learning and memory and AD-like neuropathological changes.

Experimental Rationale
Many studies have investigated the effects of calcium dysregulation on specific
AD pathologies, such as Aβ and tau, in cell culture preparations. Sparse data exist on the
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effects of in vivo calcium dysregulation, while to date no experiments have investigated
the effects of chronic calcium perturbation. Furthermore, the behavioral consequences of
altering intracellular calcium levels are unknown. The below studies sought to determine
what effect chronic calcium dysregulation would have on learning and memory and
histological markers consistent with AD. We examined multiple hippocampallydependent tasks, including the Morris water maze (MWM) and novel object recognition
(NOR), to assess whether chronic disruption of calcium homeostasis was sufficient to
produce learning and memory impairments. We also examined protein levels of Aβ and
phosphorylated tau (ptau) to determine whether chronic calcium dysregulation led to ADlike changes in these proteins. Below we have outlined a more comprehensive review of
each of the aforementioned approaches and findings in AD.
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CHAPTER 2
REVIEW OF RELATED LITERATURE
Amyloid β Hypothesis
The Aβ protein accumulates extracellularly in AD resulting in the formation of
senile plaques, which may lead to cell damage and even cell loss. Aβ was first purified in
1984 from cerebrovascular amyloid protein by Glenner & Wong and from senile plaques
the next year by Masters et al. (1985), which was when its amino acid sequence was
determined. Various mechanisms have been proposed to account for the neurotoxicity of
Aβ peptides and senile plaques. Several studies have discovered a disruption in calcium
homeostasis following Aβ administration which could potentially lead to cell death
(Mattson et al., 1992). It has also been suggested that plaques may disturb surrounding
cytoskeletal elements by “squishing” nearby cells. Although the mechanism by which Aβ
contributes to neurodegeneration remains to be conclusively demonstrated, how the
peptide is formed has been better characterized.
Aβ is formed by the proteolytic processing of its precursor protein, APP. APP is
a membrane-spanning protein encoded for on chromosome 21. Although the
physiological function of APP remains unknown, it appears to be involved with synaptic
transmission, axonal transport, cell adhesion and support, and cholesterol metabolism (for
review, see Selkoe, 1994). Knockout (elimination of the gene product) and knockdown
(reduction in the relative amount of a gene product) studies of APP have provided some
information about its function. APP seems to play a role in muscle development or
function, and has also been implicated in the formation of long-term potentiation (LTP), a
cellular process argued to be essential for learning (Dawson et al., 1999; Douglas &
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Goddard, 1975; Kauer et al., 1988; Seabrook et al., 1999; Senechal et al., 2008). Under
physiological conditions, APP is degraded via a series of enzymatic events.
The proteolytic processing of APP results in Aβ fragments of varying length,
depending on where APP is cleaved by specific enzymes called secretases (Shoji et al.,
1992; Sisodia & Price, 1995). If APP is cleaved by alpha (α)-secretase, a soluble form of
APP (sAPP) is secreted which is readily absorbed and processed by lysosomal proteolytic
events. Cleavage by α-secretase occurs in the extracellular domain of APP within the Aβ
sequence, thus preventing the formation of the Aβ peptide (Lannfelt et al., 1995). Several
reports have demonstrated sAPP may even play a neuroprotective role (Furukawa et al.,
1996; Han et al., 2005).
The senile plaques found in AD are primarily composed of the 40 and 42 amino
acid Aβ peptides, with studies showing that Aβ42 is more neurotoxic, i.e. more damaging
to neurons, than the shorter variants (Roher et al., 1996). If APP is sequentially cleaved
by beta (β)- and gamma (γ)-secretases, this leads to the formation of 39-43 amino acid
long Aβ peptides, which are similar to the lengths of Aβ predominantly found in senile
plaques in AD (Citron et al., 1996; Golde et al., 1992).
Initially, β-secretase, also referred to as β-site APP cleaving enzyme 1 (BACE-1),
cleaves APP at its amino-terminus in the extracellular domain which is followed by γsecretase cleavage within the transmembrane domain (Vassar et al., 1999). BACE-1
inhibitors have been demonstrated to inhibit β-cleavage of APP and effectively lower Aβ
levels in vitro and in vivo (Hussain et al., 2007). Inhibitors of γ-secretase have also been
shown to reduce Aβ levels in the brain when administered to mice that overexpress a
human mutant version of APP (Dovey et al., 2001). Inhibition of either of these two

8

secretases theoretically leads to a reduction in the amount of Aβ because both β- and γsecretase are necessary in order to cleave APP in a fashion that yields the 40 or 42 amino
acid peptides known to aggregate and form plaques.
Considerable pharmacological research is being directed at developing β- and γsecretase inhibitors as therapeutic targets in an effort to reduce plaque load and perhaps
even halt the progression of the disease. However, recent failures of γ-secretase inhibitors
in particular have raised questions about the validity of this approach (Cummings, 2010).
A great deal of research has also been conducted examining the genetic underpinnings of
AD with a particular focus on genes tied to the proteolytic processing of Aβ.
Genetic linkage studies have tied familial forms of AD to the gene for APP on
chromosome 21 (Citron et al., 1992; Goate et al., 1991). Over twenty mutations in the
gene have been identified to date that are thought to be responsible for the familial earlyonset form of the disease (Chai, 2007). Individuals with any of these mutations have an
increased chance, compared to the population as a whole, of developing early-onset AD
because they have a greater amount of APP and thus produce more Aβ than normal
individuals (Citron et al., 1992; Suzuki et al., 1994). Interestingly, almost all APP
mutations are located within or adjacent to the Aβ peptide region of the precursor protein,
and thus may affect the proteolytic processing of APP (Schellenberg, 1995). Related to
the processing of APP are the presenilin (PS) genes which have also been implicated in
autosomal dominant familial AD.
The genes coding for PS proteins have been linked to early-onset AD, specifically
PS-1 on chromosome 14 and PS-2 on chromosome 1 (Levy-Lahad et al., 1995;
Sherrington et al., 1995). Similar to the aforementioned mutations in APP, PS mutations
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lead to increased Aβ production, especially production of Aβ42, a species of the peptide
known to be most toxic to neurons and overabundant in AD (Citron et al., 1997; Duff et
al., 1996; Iwatsubo et al., 1994). Investigations into PS mutations and Aβ deposition have
shown that mutations in the PS gene increase the ratio of Aβ42 to Aβ40 as compared to
non-PS mutant cases of AD (Borchelt et al., 1996). This shift in the production of Aβ42
can have significant consequences, as studies have suggested that Aβ42 aggregates more
readily than Aβ40 and is deposited early in the formation of plaques (Iwatsubo et al.,
1994; Jarrett et al., 1993). Furthermore, PS mutations seem to alter APP processing by
increasing the amount of cleavage by γ-secretase, thus increasing the production of Aβ
(DeStrooper et al., 1998; Wolfe et al., 1999). Knockout studies with animals that do not
express the PS-1 and PS-2 genes show an abolishment of γ-secretase mediated cleavage
of APP (Steiner et al., 1999; Yu et al., 2001).
Based on these findings and others, Wolfe et al. (1999) proposed the hypothesis
that PS itself is a γ-secretase, an intramembranous protease that is responsible for γcleavage of APP. Despite further evidence supporting this hypothesis, it appears that PS
and γ-secretase are not the same protein even though they are highly related (Takasugi et
al., 2003). Although PS-knockout mice seem to exhibit a complete abolishment of γsecretase activity, these animals still produce Aβ42 peptide fragments, suggesting there are
additional enzymes with activity similar to γ-secretase (Wilson et al., 2002).
While the discovery that these three genes (APP, PS-1, and PS-2) are linked to
familial AD advanced the investigation of the disorder, it is important to recognize that
they only account for a small percentage of all familial early-onset cases occurring before
65 years of age (Cruts et al., 1998). Given that more than 95% of AD cases occur after
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the age of 65, it is clear that these genetic mutations contribute only minimally to the risk
of developing the more common variant of the disease (Holmes, 2002). With that said,
much more is known about the genetics of familial early-onset AD than about sporadic,
late-onset AD.
One gene implicated in non-familial forms of AD is the gene coding for
Apolipoprotein E (ApoE). ApoE is a protein critical in regulating brain Aβ peptide levels
and trafficking lipids throughout the brain (for review, see Holtzman, 2001). ApoE is
responsible for clearing Aβ peptides from the brain across the blood-brain barrier into the
peripheral circulation (LaDu et al., 1994, 1995; Morikawa et al., 2005). Aβ peptides are
normally generated at very high levels in the brain and are cleared at an equivalent rate
(Bateman et al., 2006). Thus, even small reductions in the clearance of Aβ could result in
elevated levels of Aβ peptides and eventual plaque formation. The lipidation status of
ApoE appears to be important with regard to how well it can bind to Aβ and clear the
peptide from the brain (Tokuda et al., 2000). If ApoE is in a lipidated form, it is more
effective at clearing Aβ than if it is non-lipidated.
Another way that Aβ is cleared from the brain is through a proteolytic mechanism
involving either neprilysin (NEP) (Iwata et al., 2000) or insulin-degrading enzyme (IDE)
(Kurochkin & Goto, 1994). Inhibition of either of these proteases leads to a substantial
elevation of Aβ levels in the brain and increased plaque deposition (Dolev & Michaelson,
2004). Recent research suggests that ApoE facilitates these enzymes, allowing them to
degrade Aβ (Jiang et al., 2008). The ability of ApoE to clear Aβ is also dependent upon
the isoform or allele of ApoE.
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ApoE has three alleles: ApoE-ε2, ApoE-ε3, and ApoE-ε4, with one or two copies
of the ε4 allele leading to an increased risk of developing AD (Corder et al., 1993).
Studies with transgenic mice overexpressing APP have demonstrated ApoE isoformspecific effects on the ability of each allele to clear Aβ from the brain. The most effective
allele at eliminating Aβ is the ε2 allele, followed by the ε3 allele, with the least effective
being the ε4 allele (Holtzman, 2004). Thus, individuals with one or two ε4 alleles (two
alleles being the least effective possible form) of ApoE have a less efficient mechanism
for clearing Aβ from the brain, resulting in increased levels of the peptide (Saunders et
al., 1993).
A genetic study done by Corder et al. (1993) showed that over 90% of subjects
examined who had two copies of the ε4 allele (4/4) had AD. Almost 50% of subjects with
one copy of the ε3 and one copy of the ε4 (3/4) were affected with AD. Only about 20%
of subjects with no copies of the ε4 allele (2/2, 3/3, or 2/3) had the disease. These authors
also examined the average age of onset in individuals with one or two copies of the ε4
allele. They found that expression of it leads to a significantly earlier age of onset, with
two copies of the ε4 allele leading to an earlier onset than just one copy. While the
discovery of the ApoE gene and its relation to Aβ is critical to understanding AD
pathogenesis, the presence of the ε4 allele predisposes an individual to AD, but does not
cause the disease.
Much of the above research eventually led to the amyloid cascade hypothesis,
which suggests that abnormal Aβ production and accumulation triggers the
neurodegeneration seen in AD. Hardy & Higgins (1992) proposed that deposition of Aβ
protein is the causative factor in AD pathology and that the NFT, neuronal loss, and
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dementia that follow are a result of this deposition. They hypothesized that neurotoxic Aβ
peptides disrupt calcium homeostasis both extra- and intracellularly. This intra-neuronal
increase in calcium concentration could potentially be what leads to tau proteins within
the cell becoming hyperphosphorylated and forming PHFs, which are the primary
component of NFT. Thus, for this interpretation of the amyloid cascade hypothesis to be
correct, elevations in Aβ levels should cause hyperphosphorylation of tau and
neurofibrillary pathology to develop.
This link between Aβ and tau has been verified to some extent in animal models
and in cell culture, wherein Aβ causes an increase in tau phosphorylation (Gotz et al.,
2001; Lewis et al., 2001; Zheng et al., 2002). Transgenic mice harboring mutations in
both human APP and human Tau, as well as a mutant PS-1 allele, dubbed 3xTg-AD
mice, develop both Aβ deposits and NFT-like pathology (Oddo et al., 2003a). Studies
using these mice have demonstrated that Aβ accumulation precedes the development of
tau pathology by several months, further suggesting Aβ may promote tau
phosphorylation and aggregation (Oddo et al., 2003b). These findings with transgenic
mice must be regarded carefully however due to the rarity of these mutations in humans.
Earlier studies revealed a direct relationship between Aβ and tau phosphorylation;
the treatment of neurons with Aβ fibrils increased the immunoreactivity of ptau
(Busciglio et al., 1995). This Aβ-induced increase in tau phosphorylation may be
mediated by glycogen synthase kinase 3β (GSK-3β), one of the enzymes thought to be
responsible for phosphorylating tau, as in vitro injection of Aβ activates this enzyme
(Lovestone et al., 1996). More recently, Guo et al. (2006) observed that soluble Aβ and
tau may directly interact to promote each other’s aggregation. Thus, it is clear there is
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some relation between Aβ and tau pathology, but more studies are necessary to clarify the
connection.
Despite the amount of research supporting the amyloid cascade hypothesis, there
are several gaps between the hypothesis and data collected. First, the hypothesis is
inconsistent with the presence of senile plaques in normal aged brains similar to those
seen in AD (Crystal et al., 1988; Katzman et al., 1988; Price et al., 1991). If Aβ deposits
are the catalyst for AD neurodegeneration, then it is unlikely we would see individuals
with no cognitive impairment and widespread plaque load. Furthermore, the presence of
post-mortem senile plaques does not correlate well with the severity of dementia in AD
(Snowdon et al., 1997; Terry et al., 1991).
Secondly, in transgenic animals that overexpress either APP or one of the PS
mutations, there is no significant NFT formation or neurodegeneration despite
considerable Aβ plaque load (Hsiao et al., 1996; Takeuchi et al., 2000). Because no ADlike pathology develops in these mice except for plaques, it is difficult to argue that Aβ is
directly causing the significant neuronal loss seen in the disease. Another limitation of the
amyloid cascade hypothesis is that neurodegeneration and dementia occur in the absence
of Aβ plaques in several diseases related to the tau protein (Hutton et al., 1998;
Spillantini et al., 1998). Based on these limitations and others, the amyloid cascade
hypothesis has been adapted with a larger focus on soluble Aβ peptides as opposed to the
insoluble aggregates which form the core of plaques (Hardy, 2006).
Although the causative nature of Aβ plaques has been debated, several lines of
evidence suggest soluble Aβ peptides are neurotoxic and may be better correlates of
disease severity than insoluble Aβ (McLean et al., 1999). Specifically, the aggregation of
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Aβ monomers into small, soluble oligomers may be more closely tied to AD
pathogenesis and cognitive deficits (Cleary et al., 2005; Walsh et al., 2002). Aβ
oligomers (oAβ) inhibit LTP, impair learning and memory in animal models of AD, and
have been directly linked to synapse loss and cell death (Chafekar et al., 2008; Lesné et
al., 2006; Shankar et al., 2007; Townsend et al., 2006; Walsh et al., 2002). Unlike Aβ
monomers, oligomers cannot be degraded and cleared by IDE (Walsh et al., 2002). These
findings and others suggest the formation of oAβ in AD brains may eventually result in
the aggregation of these peptides into senile plaques. However, much more research is
necessary before a complete understanding of Aβ dynamics in AD can be reached.
Regardless of whether or not Aβ peptides are the causative agent in AD, it is
likely that they contribute to the cognitive symptoms and pathogenesis of AD. Another
pathogenic contributor to the neurodegeneration observed in AD is the tau protein which
is hyperphosphorylated resulting in NFTs and neuronal loss.

Tau Hypothesis
Tau is an intracellular protein found abundantly in the central and peripheral
nervous systems and is critical for microtubule stability, assembly, and flexibility
(Goedert et al., 1989, 1992). Microtubules are located throughout the neuron; especially
in the axon where they are essential for neurotransmission, axonal transport and axonal
support (Kraemer et al., 2003; Paulson & McClure, 1974; Weingarten et al., 1975). Tau is
a phosphoprotein which implies that it requires phosphorylation, or the addition of a
phosphate group, in order for it to become activated (Butler & Shelanski, 1986). Tau is
partially phosphorylated in the normal brain and this phosphorylation may regulate
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microtubule stability and assembly (Lindwall & Cole, 1984). This microtubule regulation
appears to occur by reducing tau’s binding to tubulin, a protein that makes up
microtubules, and reducing the promotion of microtubule assembly (Hasegawa, 2004).
Thus, the phosphorylation of tau plays a pivotal role in regulating microtubule production
by reducing the amount of microtubule assembly and decreasing the ability of tau to bind
to tubulin.
In AD, the tau protein is hyperphosphorylated, which leads to the destruction of
microtubule assemblies via the aforementioned mechanisms (Grundke-Iqbal et al., 1986).
The degradation of microtubules may cause impaired axonal transport and possibly cell
death (Kosik et al., 1986). Tau hyperphosphorylation renders tau unable to bind to
microtubules, an event proposed to be responsible for tau aggregation and self-assembly
into PHFs (Bramblett et al., 1993; Goedert et al., 1988; Yoshida & Ihara, 1993). These
PHFs, which are primarily made up of hyperphosphorylated tau, correlate strongly with
neuronal death in AD (Gomez-Isla et al., 1997). Also, whereas Aβ pathology is relatively
specific to AD, NFT formation occurs in other diseases/disorders related to tau,
collectively referred to as tauopathies.
In 1998, several mutations in the tau gene were discovered in families with
frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), a
related but distinct neurodegenerative disease, producing genetic evidence that tau
abnormalities may be sufficient to lead to neurodegeneration (Hong et al., 1998; Hutton
et al., 1998; Poorkaj et al., 1998; Spillantini et al., 1998). This discovery led to the
production of many different transgenic lines of mice with tau mutations. One specific
line, the P301L mice, shows significant age-dependent NFT formation, memory
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impairment, and neuron loss (Lewis et al., 2000; Ramsden et al., 2005). Although there is
significant neurodegeneration in these animals, they do not develop any Aβ pathology,
implying that tau mutation or tangle formation are not sufficient on their own to cause
senile plaques in an animal model of AD. These findings provide strong evidence that tau
may induce neuronal loss in the absence of Aβ, but also suggest that Aβ plaque formation
may lie upstream of tau, at least for AD.
Consistent with the findings that Aβ plaque burden does not correlate well with
the severity of dementia but NFT formation does, is the finding that NFTs can be
differentiated into neuropathological stages in AD. Braak & Braak (1991) reported
detailed pathological studies about the distribution of plaques and tangles in post-mortem
brains of demented and non-demented individuals. They showed that Aβ deposition was
of little significance in relation to neuropathological staging, whereas NFTs exhibited a
neuroanatomical distribution pattern permitting the differentiation of six stages of disease
progression in AD.
Tangles are first observed in the entorhinal cortex where neuronal loss occurs
earliest, and are closely related to the initial memory impairment in AD. Conversely, Aβ
deposits are not found in the hippocampal formation until the late stages of the disease
(Hasegawa, 2004). Another post-mortem study showed that both NFTs and neuronal loss
increased in parallel with the duration of AD, although the amount of neuronal loss was
quite larger than the amount of tangle accumulation (Gomez-Isla et al., 1997). In contrast,
the authors found that the amount of plaques and Aβ accumulation was not related to
neuronal loss, the number of NFTs, or the duration of the disease.
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Despite the recent attention the tau hypothesis has received, it has limitations
similar to the Aβ hypothesis. Foremost is the finding that NFTs are extremely common
and perhaps universal in the nucleus basalis of Meynert, a basal forebrain region rich in
cholinergic fibers, in non-demented aged individuals (Beach et al., 1998). Secondly,
because humans with, or animal models of, tauopathies fail to develop Aβ pathology or
the global neuronal loss seen in AD, it is difficult to claim that tau aggregation and NFTs
are causing the disease.
Recently, soluble tau proteins have been suggested to account for neurotoxicity
and cognitive deficits as opposed to insoluble tau aggregates and NFTs. In an inducible
transgenic mouse model carrying mutant tau, the suppression of the transgene with
doxycycline in the rodents’ diet led to the amelioration of learning and memory
impairments. Interestingly, this improvement occurred despite the lack of reduction in
NFTs observed in these mice, indicating soluble tau may have been responsible for the
deficits (Santacruz et al., 2005). These results were corroborated in a drosophila (fruit fly)
model of tauopathy where it was found that soluble ptau contributed to
neurodegeneration (Feuillette et al., 2010).
These findings suggest that, similar to Aβ, soluble species of ptau may be
especially damaging, and their sequestration into NFTs may represent an attempt at a
compensatory or protective response (Alonso Adel et al., 2006; Castellani et al., 2008).
More data are certainly necessary before any conclusions can be drawn about what form
of tau (soluble or insoluble) contributes to the neurodegeneration and cognitive
impairments observed in AD. Another possible explanation for the significant neuronal
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loss and degeneration seen in AD is related to the cholinergic hypothesis and the loss of
cholinergic neurons in areas important for learning and memory.

Cholinergic Hypothesis
The cholinergic deficit in AD is the earliest and most frequently reproduced
finding, specifically the profound reduction in choline acetyltransferase (ChAT) activity
(Bowen et al., 1982; Davies & Maloney, 1976). ChAT is the enzyme responsible for
synthesizing acetylcholine (ACh), and its decreased activity leads to reduced amounts of
available ACh in the brain, specifically in the hippocampus and neocortex (Davies, 1979;
Perry et al., 1977). The finding that cholinergic cell loss is associated with the presence of
plaques in non-demented aged individuals suggests that the loss of cholinergic neurons
precedes the clinical diagnosis of AD (Beach et al., 1997). Furthermore, studies indicate
that the severity of the dementia in AD correlates well with the extent of cholinergic loss
and the reduction in ChAT activity in the cortex (Perry et al., 1981).
Cholinergic loss occurs first and foremost in the basal forebrain where CBF
neurons deteriorate very early in the disease progression (Beach et al., 2000; Bowen et
al., 1982; Whitehouse et al., 1982). ACh has been implicated in multiple cognitive
functions such as learning and memory (Cox & Tye, 1973; Spencer et al., 1985; Spencer
& Lal, 1983; Valentino & Dingledine, 1981; Whitehouse, 1967; Woolf, 1996). Once
ACh is released, it can bind to either of two receptor subtypes: nicotinic acetylcholine
receptors or muscarinic acetylcholine receptors (Role & Berg, 1996; reviewed in Ishii &
Kurachi, 2003 and Wevers & Schroder, 1999).
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Nicotinic receptors are ionotropic receptors (receptors that can open ion channels
when ACh binds to them) while muscarinic receptors are metabotropic receptors
(receptors that activate a G-protein and trigger intracellular events when ACh binds,
including the opening of multiple ion channels). There appears to be a selective loss of
ACh receptors in the cortex and hippocampus in AD, which seems to be more
pronounced for nicotinic receptors (Flynn & Mash, 1986; Perry et al., 1995; Wevers et
al., 2000).
Nicotinic receptor activation using nicotine produces a significant increase in the
amount of ptau both in vitro and in 3xTg-AD mice (Hellstrom-Lindahl et al., 2000; Oddo
et al., 2005). The exact mechanism of how this increase in phosphorylation occurs
remains unclear, but it may be a result of increased calcium levels due to overactivation
of the nicotinic receptors. Nicotonic receptors are one of only a few ionotropic receptors
in the brain that allow an influx of calcium ions when ACh binds (McGehee et al., 1995;
Role & Berg, 1996). This increase in intracellular calcium may activate different
calcium-dependent kinases, such as GSK-3β, which may be responsible for
phosphorylating tau (Oddo et al., 2005).
Nicotinic receptor activation also appears to have an effect on Aβ deposits in the
brain. In vitro studies have shown that nicotine seems to inhibit Aβ fibril formation and
also disrupts already formed fibrils (Ono et al., 2002; Salomon et al., 1996; Zeng et al.,
2001). These findings would suggest that in the absence of ACh, the formation of fibrils
is allowed to progress at a more rapid rate. Studies using Tg2576 mice, which
overexpress human mutant APP, showed a dramatic decrease both in Aβ plaque burden
and the levels of insoluble Aβ40 and Aβ42 after chronic administration of nicotine for a
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period of five and a half months (Nordberg et al., 2002). It is difficult to determine what
effect the loss of nicotinic receptors has on tau phosphorylation and Aβ deposits in AD,
and more studies are necessary to elucidate the relationships. Furthermore,
epidemiological studies linking cigarette smoking to incidence of AD have demonstrated
conflicting results (Brenner et al., 1993; Cataldo et al., 2010).
Muscarinic receptors, specifically the M1 receptor subtype, are highly expressed
in the cerebral cortex and hippocampus, and seem to be particularly relevant to memory
function in AD (Anagnostaras et al., 2003). Activation of the M1 receptor has been
shown to decrease tau phosphorylation, suggesting that decreased cholinergic activity
may lead to destabilization of the microtubule network and eventual tangle formation. In
vitro studies using cholinergic M1 agonists showed that the muscarinic-activated
decrease of tau phosphorylation was both time and dose dependent (Sadot et al., 1996). In
vivo studies using 3xTg-AD mice also showed a reduction in tau phosphorylation
following administration of a muscarinic agonist and conversely showed increased tau
phosphorylation after treatment with an M1 antagonist (Caccamo et al., 2006). Previous
in vitro findings found that M1 receptor agonists decrease tau phosphorylation via
reduction of GSK-3β activity (Forlenza et al., 2000), which appears to be the mechanism
by which tau phosphorylation was decreased in the 3xTg-AD mice.
Muscarinic receptor activation also appears to reduce Aβ production and increase
the secretion of soluble APP (Buxbaum et al., 1992). In the 3xTg-AD mice, an M1
agonist reduced Aβ deposition in the hippocampus and cortex, and ameliorated cognitive
deficits in a spatial memory task (Caccamo et al., 2006). This finding that muscarinic
activation regulates APP processing (Nitsch et al., 1992) formed the basis for the
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hypothesis that AChE inhibitors may slow disease progression by reducing Aβ
production (Inestrosa et al., 1996).
AChE inhibitors were developed as a result of the cholinergic hypothesis in order
to increase cholinergic tone in individuals with AD (Bartus, 1979; Bartus et al., 1982;
Davis et al., 1978). AChE is primarily responsible for the breakdown of ACh into choline
and acetic acid. AChE has also been implicated in Aβ plaque formation and appears to
have the ability to accelerate Aβ formation and deposition in AD (Inestrosa et al., 1996).
Therefore, by inhibiting the enzymatic activity of AChE, it may be possible to reduce Aβ
plaque formation and ameliorate AD symptomology. AChE inhibitors increase the
amount of ACh available in the synapse as well as enhance and prolong its action on ACh
receptors (Harvey & Rowan, 1990). AChE inhibitors have been approved for use in mild
to moderate AD and have been shown to improve cognitive deficits (Rogers et al., 1998;
Rosler et al., 1999; Tariot et al., 2000). These drugs tend to show symptomatic efficacy,
but little evidence exists that they prevent or even slow the course of the disease.

Neuroinflammatory Hypothesis
Glial cells in the brain, specifically microglia and astrocytes, can serve as
mediators of the inflammatory response when necessary, defending the central nervous
system (CNS) from pathogens and aiding in the recovery from damage and stress
(reviewed in Skaper, 2007). AD brains exhibit extensive localized activation of both
microglia and astrocytes in response to neuronal and synaptic damage and Aβ
accumulation (Akiyama et al., 2000). It is likely that this inflammation related to AD
pathology may be both beneficial as a mechanism to promote neuronal survival and
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detrimental to AD brain function and the degeneration process (Wyss-Coray & Mucke,
2002).
Studies have shown that aggregated Aβ is itself capable of activating the
inflammatory response by activating microglia and enhancing the synthesis and release of
proinflammatory cytokines (Combs et al., 2001; Tan et al., 1999). These proinflammatory
cytokines may also accelerate tau pathology and NFT formation, perhaps linking Aβinduced inflammation and neurofibrillary pathology (Guo et al., 2006; Quintanilla et al.,
2004; Sheng et al., 2000). These findings would suggest that inflammation is actually
advancing AD pathology and accelerating the neuronal loss.
Although microglial activation in AD may be caused by Aβ pathology, microglial
activity correlates more closely with NFT pathology (Hayes et al., 2002). This
relationship suggests that although Aβ may trigger the initial activation of microglia, the
resulting inflammatory response may be more directly related to tau pathology (BlurtonJones & LaFerla, 2006).

Calcium Hypothesis
Calcium is critical for a host of intracellular processes. For example, the release of
neurotransmitter from presynaptic terminals relies on calcium influx in order to mobilize
synaptic vesicles (Borst & Sakmann, 1996; Kochubey et al., 2011). In the absence of
calcium, transmitter will not be released following an action potential. In the postsynaptic
neuron, calcium acts as a second messenger, initiating signal transduction pathways and
even regulating transcriptional events (Bading et al., 1993; Greenberg et al., 1986).
Specifically, many enzymes such as calcium/calmodulin-dependent protein kinase II
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(CaMKII), one of the most abundant kinases (enzyme that phosphorylates other proteins)
in the brain, and cAMP-dependent protein kinase (PKA) both rely on calcium for
activation (Braun & Schulman, 1995; Impey et al., 1998). These kinases then initiate
signaling cascades which lead to downstream nuclear transcription. Calcium also plays a
direct role in synaptic plasticity; activation of N-methyl D-aspartate (NMDA) glutamate
receptors and the subsequent influx of calcium ions are necessary for the induction of
LTP and many forms of learning.
Calcium influx from the extracellular fluid can occur through ligand-gated ion
channels such as the NMDA receptor and several voltage-gated calcium channels
(VGCC) such as L-, N-, P-, and T-type channels (reviewed by Catterall, 2011). Calcium
also enters the cytoplasm from intracellular stores such as the endoplasmic reticulum
(ER) through multiple channels. Although calcium is constantly entering neurons, levels
of intracellular calcium are kept extremely low (~10-7 M) and tightly regulated by a host
of mechanisms.
A variety of adenosine triphosphate (ATP)-dependent pumps removes calcium
from the cytoplasm, either sequestering it into intracellular organelles or expelling it into
the extracellular fluid. The plasma-membrane calcium-ATPase (PMCA) efficiently
pumps calcium ions out of neurons, while the sarco/endoplasmic reticulum calciumATPase (SERCA) pump sequesters intracellular calcium into the ER (Gunteski-Hamblin
et al., 1988; Strehler et al., 2007). These pumps require a great deal of energy expenditure
from the cell in order to maintain the low levels of intracellular calcium and high
sensitivity for the ion. Other membrane-bound mechanisms do not utilize ATP to extrude
calcium but instead rely on its electrochemical gradient.
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The sodium/calcium exchanger, an ion transporter localized primarily to the
plasma membrane, removes one calcium ion from the cytoplasm for every three sodium
ions that flow into the cell. However, this process is reversible and completely dependent
upon the electrochemical gradient of potassium, sodium, and calcium, as well as the
membrane potential of the cell (Blaustein & Lederer, 1999). This exchanger is likely the
predominant mechanism for calcium efflux across the plasma membrane, especially
when intracellular calcium levels are elevated due to a high rate of neuronal activity
(Lytton, 2007).
High rates of activity may also lead to calcium uptake into mitochondria via
mitochondrial calcium uniporters (DeLuca & Engstrom, 1961). These calcium
transporters bring calcium across the mitochondrial membrane using the electrochemical
gradient of calcium and the mitochondrial membrane potential (Kirichok et al., 2004).
Although these uniporters are important for sequestering excess calcium, sustained
elevation of calcium levels in the mitochondria can be dangerous and lead to cell death.
Additional mechanisms responsible for regulating intracellular calcium levels
include calcium-binding proteins such as parvalbumin (PV) and calbindin (CB). This
class of proteins plays a significant role in the buffering of intracellular calcium, thereby
reducing the likelihood of excessive mitochondrial calcium uptake and subsequent
apoptosis (Rintoul et al., 2001). All of the mechanisms mentioned above play a role in
maintaining calcium homeostasis and preventing excessive intracellular calcium levels.
When this homeostasis cannot be maintained, the consequences for both an individual
neuron and the brain can be severe.
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Excessive calcium influx, often mediated by NMDA receptor calcium channels,
can be toxic for cells, a phenomenon known as excitotoxicity (Choi, 1985; Lucas &
Newhouse, 1957). Interestingly, this phenomenon is a common occurrence in several
neurodegenerative diseases including Huntington’s disease, Parkinson's disease, and
amyotrophic lateral sclerosis (ALS) (Beal, 1998; Cluskey & Ramsden, 2001; TaylorRobinson et al., 1994). These consistent findings across disorders suggest excitotoxicity
may play an integral role in age-related neurodegeneration. Excitotoxicity also occurs in
later stages of AD (Mattson, 1994). However, a sustained, low-level calcium
dysregulation may have an impact in early or preclinical AD as well.
Disruptions of calcium regulation have been consistently observed in aged and
AD brains (Ito et al., 1994; Peterson et al., 1985; Peterson & Goldman, 1986; Raza et al.,
2007), potentially contributing to neurodegeneration in AD. Calcium levels are increased
in neurons that contain NFTs as compared with tangle-free neurons (Murray et al., 1992).
The increased levels of calcium may even precede tangle formation as levels of CaMKII
are increased in hippocampal neurons vulnerable to degeneration (McKee et al., 1990).
Tau mutations, similar to those found in FTDP-17, lead to altered calcium channel
function and increased calcium influx (Furukawa et al., 2003). Similarly, an increase in
Aβ production has been observed as a result of calcium influx in vitro (Querfurth &
Selkoe, 1994; Pierrot et al., 2004). In 3xTg-AD mice, an increased resting calcium
concentration is observed (Lopez et al., 2008; Vale et al., 2010). These studies and others
mentioned above implicate perturbed calcium homeostasis as a major pathogenic
contributor in AD, with an emphasis on the role of calcium derived from intracellular
stores such as the ER and mitochondria.
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Mitochondrial dysfunction has been consistently observed in both aged and AD
brains, possibly contributing to the neurological changes seen in the disorder (Leslie et
al., 1985; Mancuso et al., 2006; Sheehan et al., 1997). Mitochondria are involved in
maintaining calcium homeostasis and allow calcium entry through a variety of
mechanisms (Beutner et al., 2005; Nicholls, 2005; Sparagna et al., 1995). Excessive
calcium intake by mitochondria has been shown to increase reactive oxygen species
(ROS), inhibit ATP synthesis, open the mitochondrial permeability transition pore
(mPTP), and induce the release of pro-apoptotic factors (Brustovetsky et al., 2003; Jiang
et al., 2001). Therefore, it is possible that increased intracellular calcium levels may lead
to mitochondria-induced apoptosis which may account for some of the neuronal loss
witnessed in AD. The ER, another important intracellular mediator of calcium levels, has
also been implicated in AD pathological dysfunction.
The ER is a crucial organelle for the synthesis, correct folding, and transport of
proteins which are integral for normal cellular function (reviewed in Paschen &
Mengesdorf, 2005). The ER is also central in cellular calcium storage and signaling, as
high levels of calcium are necessary for proper protein synthesis and folding (Kuznetsov
et al., 1992; Pozzo-Miller et al., 1997). Disruptions of normal ER functioning, termed ER
stress, have been observed in AD and may contribute to the pathological disturbances
(Katayama et al., 2004; LaFerla, 2002; Verkhratsky, 2005).
Under conditions of ER stress, signaling pathways may be activated in an attempt
to counteract the stress, the most notable one being the unfolded protein response (UPR).
The main purpose of the UPR is to restore normal ER functioning by reducing the
amount of proteins that need to be folded and processed, while also increasing the protein
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folding and processing capacity in the ER (Kaufman, 1999). However, if the stress is
prolonged or severe, as may be the case in AD, the ER may initiate cell death pathways
(Unterberger et al., 2006). The finding that PS proteins are localized on the ER
membrane (Kovacs et al., 1996), in addition to their role in the γ-secretase complex,
provided a critical link between known AD genetic phenomena and intracellular calcium
regulation.
As mentioned above, PS mutations lead to increased production of neurotoxic Aβ
and disruption of intracellular calcium homeostasis (Duff et al., 1996). This calcium
disruption associated with PS mutations has been consistently demonstrated in several
different neuronal preparations, both from familial AD tissue and animal models with PS
mutations (Ito et al., 1994; Herms et al., 2003; Stutzmann et al., 2004). It is clear that PS
proteins play a role in calcium regulation, however only recently has this role been
elucidated. Studies have demonstrated that PS mutations lead to greatly exaggerated
calcium liberation from ER stores after cellular stimulation (Ito et al., 1994; Leissring et
al., 1999; Mattson et al., 2000; Stutzmann et al., 2004).
Several mechanisms have been proposed to explain how PS mutations alter
functioning in the ER. One proposed mechanism suggests that PS mutations alter PS leak
channel activity, leading to increased calcium levels within the ER (Nelson et al., 2007;
Tu et al., 2006). Another study posits that PS mutations may increase inositol 1,4,5triphosphate receptor (IP3-R) activity, leading to increased calcium release from the ER
(Cheung et al., 2008).
A third mechanism suggests that PS-mediated calcium dysregulation occurs
through upregulation of the ryanodine receptor (RyR), an ER calcium channel
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responsible for calcium-induced calcium release (CICR) from the ER (Smith et al., 2005;
Stutzmann et al., 2006). Recently, Stutzmann and colleagues found dramatically
increased RyR expression in 3xTg-AD mice at an age before any cognitive deficits or
neuropathological hallmarks are exhibited (Chakroborty et al., 2009). Their findings
imply that perturbed, yet functional, calcium signaling occurs before AD-like events such
as plaques and tangles. Thus, it is possible altered calcium signaling may facilitate
development of the pathologies seen in AD.
The RyR is widely expressed throughout the mammalian brain (McPherson &
Campbell, 1993). It is an important regulator of intracellular calcium homeostasis and a
critical mediator of calcium release from the ER (Mignery et al., 1989; Shmigol et al.,
1995). The RyR is especially crucial for calcium-mediated presynaptic neurotransmitter
release (Padua et al., 1996). AD brains display a significant impairment in RyR
functioning which likely occurs early in AD pathogenesis and correlates well with the
development of plaques and tangles (Kelliher et al., 1999).
Early studies by Querfurth et al. (1997) demonstrated that administration of
caffeine, a potent activator of RyRs, increased Aβ production in human embryonic
kidney (HEK) 293 cells. Further, caffeine-induced calcium release is enhanced in 3xTgAD mice, likely due to the increased expression of RyRs observed in these mice (Smith
et al., 2005). These findings imply a bidirectional or feed-forward relationship between
RyR activation and prominent AD pathologies. It is unclear what role the RyR plays in
AD pathogenesis or if abnormal function of this channel is sufficient to induce AD-like
neurodegeneration and cognitive deficits. Studies using in vivo models to investigate
RyR-mediated calcium dysregulation may be necessary to answer these questions.
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Several additional mechanisms for maintaining calcium homeostasis in the cell exist,
especially in the ER.
ER calcium levels in the brain are largely regulated by SERCA (Miller et al.,
1991), which pumps calcium back into the ER to maintain equilibrium. Disruption of
normal SERCA activity with thapsigargin, an irreversible SERCA inhibitor, leads to a
sharp spike in cytosolic calcium levels using in vitro methods (Lytton et al., 1991). This
SERCA inhibition prevents refilling of ER calcium pools which creates a sustained level
of increased intracellular calcium.
Various cell culture systems have taken advantage of thapsigargin to investigate
AD-like calcium dysregulation. Seminal investigations by Buxbaum et al. (1994)
demonstrated that thapsigargin can dose-dependently alter APP processing and levels of
Aβ in Chinese hamster ovary (CHO) cells. Additional studies have shown that
thapsigargin leads to increased Aβ levels in neuronal and non-neuronal preparations
(Crestini et al., 2011; Querfurth et al., 1997).
Intracellular calcium dysregulation via thapsigargin can also increase tau
phosphorylation both in primary neuronal cultures (Ho et al., 2012) and following acute
in vivo administration of the compound (Fu et al., 2010). Collectively, these studies
suggest that thapsigargin-induced calcium dysregulation may produce cellular changes
consistent with AD. Although calcium dysregulation is centrally implicated in AD, the
calcium hypothesis has suffered from a lack of genetic evidence until recently.
A novel calcium channel, named calcium homeostasis modulator 1 (CALHM1),
was discovered with polymorphisms associated with an increased risk for AD (DresesWerringloer et al., 2008). CALHM1 is a transmembrane protein found predominantly in
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the ER and neuronal membranes and is unaffected by blockers of voltage-gated calcium
channels. Interestingly, calcium influx through this channel decreases Aβ production and
increases the soluble form of APP produced after cleavage by α-secretase. CALHM1 may
also interfere with ER calcium handling and trigger ER stress (Gallego-Sandin et al.,
2011). The polymorphism found in CALHM1 has been shown to increase Aβ production,
providing direct genetic evidence of a link between calcium dysregulation and AD
pathology. These findings have been somewhat controversial however, and other
populations have failed to exhibit an association between the CALHM1 polymorphism
and AD (Beecham et al., 2009; Bertram et al., 2008; Minster et al., 2009; Sleegers et al.,
2009; Tan et al., 2011).

Experiments and Hypotheses
Current animal models of AD almost exclusively rely on genetic mutations that
only occur in familial, early-onset cases of the disease. They are valuable tools for
investigating specific pathologies such as Aβ and tau dysfunction, but these models do
not have great utility in studying the mechanisms underlying AD pathogenesis. Most
investigations of AD examine prominent pathologies (i.e. plaques and tangles) in order to
observe their effect on normal functioning. An alternative approach is to examine
neurochemical changes upstream, pathologically and temporally, of these gross lesions.
The amount of data generated investigating mechanistic approaches upstream of
Aβ and tau is scarce. As mentioned above, calcium can directly influence the processing
of APP and the phosphorylation state of tau. Alterations in the regulation of calcium may
represent an upstream mechanism capable of explaining the aberrant Aβ and tau activity

31

observed in AD. This calcium dysregulation may then be exacerbated by the pathologies
it produced in a neurodegenerative feed-forward loop. Because the effects of in vivo
calcium dysregulation are unknown, it is unclear whether this hypothesis has validity.
In the below experiments, we examined a novel approach to AD by inducing a chronic
dysregulation of intracellular calcium. Current AD models typically produce robust
impairments in hippocampal-dependent learning and memory using tasks such as the
MWM and NOR testing, as well as pathological disturbances consistent with AD (Cleary
et al., 2005; Hsiao et al., 1996). We hypothesized that our manipulations would produce
behavioral and neurochemical changes similar to what is observed in other animal models
of AD.
This model was the first to investigate the effects of chronic perturbation of
calcium homeostasis in an in vivo system. In order to disrupt calcium levels, we utilized
ryanodine, a dose-dependent agonist of the RyR, and thapsigargin, the aforementioned
SERCA inhibitor. The chronic, steady infusion of each of these compounds should
produce a sustained elevation of cytosolic calcium. The effect of this prolonged calcium
dysregulation in vivo is unknown; to the best of our knowledge, this series of studies was
the first to examine it. Three experiments were performed, each of which is outlined
below and summarized in Table 1.

Experiment 1
The effects of chronic intracellular calcium dysregulation were initially examined
in a pilot study using ryanodine or thapsigargin centrally administered to adult male rats.
Ryanodine was administered at a dose of 250 nM while thapsigargin was administered at
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10 µM. Alzet osmotic mini-pumps were implanted subcutaneously and connected to a
cannula, which infused the compound directly into the lateral ventricles. The osmotic
mini-pump releases solution at a rate of 0.15 µL/hour over the course of six weeks.
Following four weeks of infusion, learning and memory was examined in NOR and the
MWM in subsequent weeks before tissue was collected at the six week point. We
examined the brains for any changes in protein levels that are consistent with those
observed in AD. Tau phosphorylation, an early and consistent event in AD, was
investigated at the Serine 396 epitope (pTau396 antibody). Total tau protein levels were
also examined (Tau-5 antibody) to determine if chronic calcium dysregulation altered any
aspect of tau expression.
We also examined protein levels of oAβ following treatment with thapsigargin or
ryanodine, as evidence suggests oAβ may best correlate with disease severity (McLean et
al., 1999). Because amyloid deposits are rarely if ever found in rodent brains, likely due
to the slight but significant differences in the sequence of Aβ versus humans (Otvos et al.,
1993), plaque load would not be a feasible measure to evaluate. These oligomers may
represent an intermediate step between the easily cleared Aβ monomers and the insoluble
fibrillar plaques observed in AD, making them ideally suited to investigate in a potential
model of preclinical AD.
Finally we investigated protein levels of calbindin-D28k (CB-D28k), a calcium
buffering protein that also likely acts as a calcium sensor, directly affecting intracellular
signaling pathways (Schwaller, 2010). If thapsigargin or ryanodine perturbed calcium
regulation, this change should be reflected in CB-D28k levels. Prolonged increases in
intracellular calcium concentration may lead to excessive calcium binding to calcium
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buffers such as CB-D28k. In turn, this may alter the neuronal expression of CB-D28k, a
change which should be reflected in its protein levels.

Experiment 2
In order to determine the optimal effective dose of each ligand to produce
behavioral deficits and AD-like neurochemical changes, ryanodine and thapsigargin were
each administered to adult male rats at two different doses: ryanodine at 1 or 5 µM and
thapsigargin at 20 or 40 µM. All other methods and timelines were identical to
experiment 1 with the exception that more subjects per group were utilized in experiment
2.

Experiment 3
Neuroinflammation has been increasingly implicated as an important aspect of
AD progression and onset (Hensley, 2010). Recent genetic evidence even suggests that
variants in the triggering receptor expressed on myeloid cells 2 (TREM2) gene may be a
risk factor for AD (Guerreiro et al., 2013; Jonsson et al., 2013). TREM2 is a phagocytic
immune receptor expressed on the cell surface of microglia and is essential for the
clearance of neuronal debris (Singaraja, 2013). Coupled with many other recent studies
investigating the role of inflammation in neurodegeneration, the investigation of
neuroimmune interactions with AD pathology has become a hot topic.
In a follow-up study to experiment 2, we investigated the interaction between
chronic calcium dysregulation and inflammation. Because thapsigargin displayed more
promise as a potential inducer of AD-like calcium dysregulation in our previous studies,
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it was favored in experiment 3 over ryanodine. To induce the inflammatory response,
lipopolysaccharide (LPS) was systemically administered to rats two weeks following
surgical implantation of the Alzet osmotic pumps. LPS is derived from gram-negative
bacteria and induces a strong immune response in the brain, including robust, long-lasting
activation of microglia (Herber et al., 2006) and cytokines (Murray et al., 2011). Aged
rats (10-12 months of age) were utilized to better reflect how closely our model
mimicked prodromal AD, while the dosage of thapsigargin chronically administered was
designed to be 25 µM in this experiment. Unfortunately, due to an error in filling the
osmotic pumps, a combination of 25 µM and 40 µM thapsigargin was introduced into the
pumps, a mistake not realized until after the experiment was finished or any corrections
could be made. This error prevented a precise knowledge of what drug concentration was
in the pumps and therefore all interpretations of the data from this experiment were made
with extreme caution. Pumps administered the compounds for five weeks before
behavioral testing commenced and tissue was collected seven weeks following surgery.
All other methods and biochemical targets were consistent with experiments 1 and 2.
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CHAPTER 3
MATERIALS AND METHODS
Subjects
For experiment 1, twenty-four male Sprague-Dawley (SD) rats (n=8)
approximately three months of age at arrival were purchased from Charles River
Laboratories; for experiment 2, sixty male SD rats (n=12) approximately three months of
age at arrival were purchased from Charles River; for experiment 3, forty (n=10) male
retired breeder rats approximately nine to eleven months of age at arrival were purchased
from Taconic Farms. Rats were maintained in a temperature and humidity (22 ± 1°C)
controlled facility, with food and water available ad libitum, on a 12:12 light/dark cycle,
lights on at 7:00 a.m. In experiments 1 and 2, animals were housed in pairs until the time
of the surgery, after which they were individually housed. In experiment 3, rats were
individually housed upon arrival. All procedures were approved by the University of
Nevada, Las Vegas Institutional Animal Care and Use Committee and were carried out in
accordance with NIH guidelines for the appropriate care and use of animals.

Surgery
Surgeries were performed under aseptic conditions and a cocktail of ketamine (80
mg/kg) and dexmedetomidine (0.2 mg/kg) anesthesia as previously described (Kinney et
al., 2003; Sabbagh et al., 2012). A guide cannula was implanted into the right lateral
ventricle at coordinates 0.7 mm posterior and 2 mm lateral to bregma and 3.5 mm ventral
to the surface of the skull (Paxinos & Watson, 1986. Three indentations were made in the
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skull to allow threading of jeweler’s screws, which were placed on the skull to anchor the
cannula in place.
A catheter attached to an Alzet osmotic pump was then attached to the cannula
and the pump was subcutaneously implanted between the scapulae. Dental acrylic was
applied to bind together the screws, the base of the cannula, and the skull. Sutures were
then applied to close up the wound followed by the removal of the animal from the
device. Once the rats were ambulatory they were administered an analgesic,
buprenorphine (0.05 mg/kg), intraperitoneally and soon after returned to the colony room.
Buprenorphine (0.05 mg/kg) was administered daily for two days following the surgery
to reduce post-operative pain. Following surgery animals were individually housed and
left undisturbed for a minimum of one week.

Drug Treatments
Ryanodine (Tocris Biosciences, Ellisville, MO) was dissolved in artificial
cerebrospinal fluid (ACSF) to a final concentration of either 250 nM, 1 µM, or 5 µM.
Thapsigargin (Sigma-Aldrich, St. Louis, MO) was diluted in ACSF to a final
concentration of either 10, 20, 25 or 40 µM. LPS was dissolved in saline and injected
intraperitoneally at a concentration of 1 mg/kg. Mini-pumps were filled with ryanodine,
thapsigargin, or vehicle, depending on the experiment. Pumps infused the compounds
into the ventricular fluid at a steady rate over the course of 6-7 weeks (0.15 µL/hour).
Table 1 outlines the drug administrations for each experiment.
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Table 1.
Outline of the groups for each experiment with drug dosages.
Experiment 1 (n=8)

Experiment 2 (n=12)

Experiment 3 (n=11)

Vehicle

Vehicle

Ryanodine (1 µM)

LPS (1 mg/kg)

Vehicle

Ryanodine (5 µM)
Ryanodine (250 nM)

Thapsigargin (25-40 µM)
Thapsigargin (20 µM)

Thapsigargin (10 µM)

Thapsigargin (40 µM)

Thapsigargin + LPS

Behavioral Testing
One week following surgery once rats had sufficient time to recover, animals
were briefly handled three times a week to ensure consistent data. Behavioral testing
commenced an average of four weeks following the surgeries in experiments 1 and 2 and
five weeks following surgery in experiment 3. Open field and NOR testing occurred
during the first week of testing and the MWM began the following week. See figure 1 for
a timeline of experiments.
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Experiments'1'&'2'
Week'1'

Week'2'

Week'3'

Week'4'

Week'5'

Week'6'

Open'Field'and'
NOR'tes<ng'

Surgery'

MWM'

Experiment'3'
Week'1'

Surgery'

Week'2'

Week'3'

Week'4'

Week'5'

LPS'injec<on'

Week'6'

Week'7'

Open'Field'and'
NOR'tes<ng'

MWM'

Figure 1. Timeline of experimental manipulations and testing.

Temperature and Weight Tracking
In experiment 3, animals were probed for rectal temperature before and after
administration of LPS in order to verify illness. Temperatures were recorded in degrees
Centigrade (°C). Weights were also tracked during this time frame to detect differences
among groups.

Open Field and Novel Object Recognition Testing
The open field and NOR tasks were conducted as previously described (BertainaAnglade et al., 2011; Ennaceur & Delacour, 1988). For open field testing, rats were
placed in a large open chamber for five minutes in order to examine anxiety-like behavior
and ambulatory activity. The tracking system (Smart, San Diego Instruments, San Diego,
CA) recorded a track of the animal and data were analyzed for time spent in center, time
spent in the perimeter, and locomotor activity.
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NOR testing began the following day. A pair of identical objects (object A) were
placed in two counterbalanced corners of the chamber, and animals were allowed to
freely explore the chamber for 5 minutes while time of object exploration was recorded.
In experiment 1, a short-term memory (STM) test was performed 15 minutes later with a
novel object (object B) paired with the original object. Conducting this STM test in
experiments 2 and 3 was not feasible due to the number of subjects that needed to be run
each day within the 12:12 hour light cycle. A long-term memory (LTM) test was
performed 24 hours later in all experiments. In experiment 1, a novel object (object C)
was paired with object B. In experiments 2 and 3, a novel object (object B) was paired
with the original object (object A). Two distinct pairs of objects, previously examined to
ensure no preference exists, were counterbalanced across sessions. Each session was
recorded by video, and an analysis of total time spent investigating and preference for
novel objects was performed by trained observers for both trials when applicable. Manual
scoring was performed by multiple observers to ensure consistent data. An investigation
was defined as contact with the object or sniffing of the object within 2 cm of the
animal’s head.

Morris Water Maze
The Morris water task was conducted in a circular tank, 1.8 m in diameter and 76
cm in height, made of white polyethylene 4.7 mm in thickness (San Diego Instruments).
Tap water, 48 cm deep, was maintained at a temperature of 25°C and made opaque by the
addition of white non-toxic paint (Fresco Tempera Paint, Rich Art Color Company,
Northvale, NJ), and changed every other day. The escape platform, a square platform 10
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cm in diameter made of clear plastic, was placed in the center of one of the four
quadrants (target quadrant), 30 cm from the inside wall of the maze and 1.5 cm below the
surface of the water. For visible platform training, a large black and white cover was
attached to the top of the platform and protruded 2 cm above the water.
Trials were recorded and captured using the video tracking system (Smart)
recorded from a Sony Handycam camera connected to a Cobalt Instruments computer.
Data collected for each trial consisted of a track of the animal, which included the latency
to locate the platform, speed of swimming, and thigmotaxis. On the probe trial the
tracking system also recorded the amount of time subjects spent in each of the four
quadrants of the maze, as well as the number of times the animal’s path crossed over the
previous platform location and its analogous location in each quadrant.
For the MWM procedure, subjects were taken individually from the colony room
to a dedicated testing room containing the water maze, a computer desk, a table with the
heating cage, and large geometric shapes positioned on each of the four walls, all serving
as distal spatial cues. The rat was placed into the maze at one of three randomized
locations, in the center of a quadrant that did not contain the escape platform (non-target
quadrant). The rat was allowed to swim in the maze until it reached the hidden platform
and placed its forepaws on the platform. If after 60 seconds the animal did not locate the
hidden platform, it was guided to the platform by the experimenter. The rat was given 20
seconds on the platform to orient to distal spatial cues and was then placed under a heat
lamp for a total of 30 seconds between trials.
Three additional trials were conducted in an identical fashion, for a total of four
training trials per day. Following the fourth trial, the animal was dried and returned to its
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home cage. The training trials for the hidden platform were conducted until control
subjects reached a latency criterion of less than 15 seconds (4-trial group mean). A probe
trial was conducted five hours later in experiment 1 or twenty-four hours later in
experiments 2 and 3. For probe trials, the rat was placed in the maze in the same fashion
as during training, but the escape platform was absent. The single probe trial was 60
seconds in duration, after which the rat was dried and returned to its home cage.
The day after completion of the probe trial, a two-day visible platform training
protocol was employed. A visible platform that extends above the surface of the water
(intra-maze cue) was placed into the maze instead of the hidden platform. Four trials per
day were conducted for each animal in the same fashion as during the hidden platform
training, with the exception that the platform location was changed on each trial. Visible
platform training was conducted in order to detect any deficits in visual ability and motor
function. Animals were humanely euthanized the day following completion of the
MWM.

Tissue Collection
Animals were humanely euthanized via carbon dioxide asphyxiation and a
secondary method of euthanasia (either decapitation or cutting of the diaphragm).
Depending on the experiment, four to six rats from each group had their brains quickly
removed and frontal cortex, hippocampus, and cerebellum were dissected out and flash
frozen in dry ice. The dissected tissue was stored at -80° C until SDS/PAGE experiments.
The remaining rats from each group were utilized to verify that cannulae
terminated in the lateral ventricle. These rats were transcardially perfused with ice-cold
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phosphate-buffered saline (PBS) through the vascular system via the left ventricle of the
heart followed by perfusion of 4% paraformaldehyde (PFA) to fix the tissue. Brains were
then removed and placed in 4% PFA at 4° C for 48 hours followed by transfer to a 30%
sucrose solution in PBS. Brains remained in this solution until they were sectioned on a
cryostat to examine cannulae placement.

SDS/PAGE (Western Blots)
Tissue were homogenized in a non-denaturing lysis buffer consisting of 1X RIPA
buffer (Cell Signaling; 20 mM Tris-HCL pH 7.5, 150 mM NaCL, 1 mM Na2 EDTA, 1
mM EGTA, 1% NP-40, 1% sodium deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM
β-glycerophosphate, 1 mM Na3VO4, and 1 µg/ml leupeptin), 1 mM DTT, 1 mM
phenylmethylsulfonyl fluoride (PMSF), 20 µg/ml aprotinin and 0.1% sodium dodecyl
sulfate (SDS). Lysates were centrifuged at 15,000 x g for 15 minutes at 4°C, the
supernatant was collected, and a protein assay to determine concentration was performed
using the biciconinic acid method (BCA; Pierce, Rockford, IL). Samples (20 µg) were
separated on 10 or 12% polyacryl gels, according to the method of Laemmli (1970).
Proteins were then electro-transferred to nitropure 45 micron nitrocellulose membranes
which were blocked in 5% milk in PBS and 0.1% sodium azide for two hours.
Individual membranes were then probed overnight at 4° C with one of the
following primary antibodies diluted in 5% milk in PBS plus 0.2% Tween: rabbit
polyclonal anti-pTau396 (1:2000 dilution; Santa Cruz Biotechnology, Santa Cruz, CA),
mouse monoclonal anti-Tau-5 (1:5000; Millipore, Billerica,MA), rabbit polyclonal antiamyloid oligomer (1:1000; Millipore), mouse monoclonal anti-calbindin D-28k (1:1000;
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Sigma-Aldrich), or rabbit anti-β-actin antibody as control (1:10000; Sigma-Aldrich).
Detection of specific binding was performed by incubation with IRDye near-infrared
secondary antibodies (1:20000 for IRDye 680 or 1:10000 for IRDye 800; LiCor
Biosciences, Lincoln, NE) for one hour at room temperature. Following washes in PBS
plus 0.1% Tween, membranes were imaged on an Odyssey CLx Infrared Imaging
Sysytem (Li-Cor) and integrated intensity (I.I.) was obtained for each sample. Each
sample was run in duplicate with β-actin or tau to normalize protein levels.

Statistical Analyses
Group differences in rectal temperature or weight were analyzed by one-way
between subjects analysis of variance (ANOVA) with either treatment or group as the
factor. One-way between subjects ANOVA was also used to analyze locomotor activity
and time spent in the perimeter following open field testing with group as the factor. The
performance index (PI) of each group for NOR testing was analyzed with paired sample
t-tests. MWM hidden and visible platform training data were analyzed by repeated
measures ANOVA with days as the within subjects factor and group as the between
subjects factor, while probe trial data were analyzed by one-way within subjects ANOVA
with percent time in quadrant or annulus crossings as the factor. Western blot integrated
intensity (I.I.) data were also analyzed by one-way between subjects ANOVA with group
as the factor. Tukey post-hoc comparisons of treatment groups were performed following
any significant ANOVA to determine points of significance (p<.05).
Correlational analyses were performed to examine the relationship between water
maze performance and protein level changes in the brain. Probe trial time in target
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quadrant data for each subject were compared to the vehicle mean to yield a difference
score. Protein levels were also equated in this fashion, with individual subject data being
compared to vehicle to provide a difference score. Scatterplots were then generated to
determine if any potential correlations existed between probe trial performance and
protein levels for each experiment, as well as for each group within experiments. If
possible correlations existed, linear regression analyses were performed to determine
significance (p<.05).
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CHAPTER 4
RESULTS
Experiment 1
Open Field Testing
Experiment 1 was a pilot study to establish if altering calcium regulation would
be a tractable approach to investigate AD. In the open filed test, animals were allowed
five minutes to freely explore an open box, while percent time spent in the perimeter and
locomotor activity were recorded. No significant differences were observed in the amount
of time spent in the perimeter among groups (F2,21 = 2.050, p=.154; see figure 2A).
Similarly, neither ryanodine nor thapsigargin produced a change in the total distance
travelled versus vehicle (F2,21 = 1.732, p=.201; see figure 2B).

Percent Time Spent in Perimeter
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60%#
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Thapsigargin'
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Thapsigargin'
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Figure 2. Open field testing in experiment 1 (n=8). (A) No significant differences were
found among groups in the percent time spent in the perimeter or (B) the total distance
travelled. Data are expressed as the mean ± SEM
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Novel Object Recognition Testing
The day following open field testing, two identical objects (object A) were placed
into the open field chamber and animals were permitted five minutes to explore. There
were no significant differences among groups in the amount of time spent investigating
the identical objects (F2,21 = 1.733, p=.201; see figure 3A). In the STM test fifteen
minutes later (figure 3B), thapsigargin-treated animals did not spend significantly more
time with the novel object (object B) than chance levels (t7 = 1.639, p=.145). The groups
administered vehicle or ryanodine did not display any deficits (t7 = 2.674, p<.05 and t7 =
3.096, p<.05, respectively). Twenty-four hours later in the LTM test (figure 3C), neither
the vehicle nor thapsigargin groups spent significantly more time with a novel object
(object C) than chance levels (t7 = 0.125, p=.904 and t7 = 1.162, p=.283, respectively).
Ryanodine-treated subjects did spend significantly more time with object C than chance
(t7 = 5.333, p<.01), indicating the lack of a LTM impairment.

Morris Water Maze Testing
Subjects underwent six days of MWM hidden platform training before criterion
latency was reached in the vehicle group. For latency to reach the platform, there was a
significant main effect of days (F5,425 = 16.955, p<.01), indicating subjects significantly
improved across days. There was also a significant main effect of treatment for latency
(F2,85 = 4.281, p<.05; Tukey post-hocs revealed that thapsigargin-treated rats had
significantly longer latency versus vehicle, p<.05; figure 4A), indicating that thapsigargin
impaired ability to locate the hidden platform. There were no differences in speed of
swimming among groups during training (F2,85 = 0.795, p=.455; figure 4B), suggesting

47

neither ryanodine nor thapsigargin impaired swimming ability. There was a significant
main effect on thigmotaxis, the amount of time spent in the perimeter of the maze, but no
differences were observed among groups (F2,85 = 4.408, p<.05; Tukey post-hocs revealed
no significant differences among groups; figure 4C), suggesting the drugs did not
increase anxiety-like behavior.
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Figure 3. NOR testing in experiment 1 (n=8). (A) No significant differences among
groups were found in the total time spent investigating the original objects (object A). (B)
Thapsigargin produced a short-term memory deficit when presented with a novel object
(object B) fifteen minutes following object A. (C) Only ryanodine-treated rats spent
significantly more time with a novel object (object C) than chance levels twenty-four
hours later. Data are expressed as the mean ± SEM. * indicates p<.05 in (B) and p<.01 in
(C).

Five hours later a probe trial was conducted to assess discrete spatial learning of
the platform location (see figure 5). Within group analyses of the percent time spent in
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each quadrant were performed to evaluate if subjects spent significantly more time in the
target quadrant than each of the other three quadrants (figure 5A). The vehicle group
demonstrated a selective probe trial (F3,24 = 14.470, p<.01; Tukey post-hocs revealed
subjects spent significantly more time in the target quadrant versus each of the other
quadrants, p<.01) but ryanodine-administered rats did not show a preference for the target
(F3,24 = 9.632, p<.01; Tukey post-hocs revealed that animals spent significantly more
time in target versus the opposite and adjacent right quadrants (p<.01) but not the
adjacent left quadrant, p=.144). Surprisingly, thapsigargin did not produce a probe trial
impairment despite the deficits observed in hidden training (F3,28 = 5.056, p<.01; Tukey
post-hocs revealed subjects spent significantly more time in the target quadrant versus
each of the other quadrants, p<.05).
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Figure 4. MWM testing in experiment 1. (A) Thapsigargin produced a significant deficit
in latency to locate the hidden platform. (B) No differences were observed in speed of
swimming or (C) thigmotaxis among groups. Data are expressed as the mean ± SEM. *
indicates p<.05. Vehicle: n=7; ryanodine: n=7; thapsigargin: n=8.
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Another approach to measure probe trial performance is to record annulus
crossings, the number of times subjects crossed the target platform location and the
analogous platform locations in the other three quadrants (see figure 5B). Vehicle-treated
animals displayed a significant probe trial when annulus crossings were analyzed (F3,24 =
6.571, p<.01; Tukey post-hocs revealed subjects crossed the target platform location
significantly more times than the other three quadrants, p<.05). Both ryanodine and
thapsigargin impaired probe trial annulus crossings (ryanodine: F3,24 = 3.119, p<.05;
Tukey post-hocs showed that animals did not cross the target significantly more often
than any other quadrant, p>.05; thapsigargin: F3,28 = 1.721, p=.185).
The day following the probe trial, visible platform training was conducted to
assess general sensory and motor function. No significant differences were observed
among groups in latency to locate the visible platform (F2,85 = 1.670, p=.194; figure 4A)
or thigmotaxis (F2,85 = 2.295, p=.107; figure 4C). There were differences in speed of
swimming (F2,85 = 4.157, p<.05; Tukey post-hocs revealed that thapsigargin produced a
significant increase in swim speed during visible training versus vehicle, p<.05; figure
4B), but it is unlikely this difference altered performance due to the lack of difference in
latency.
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Figure 5. MWM probe trial performance in experiment 1. (A) Ryanodine-treated animals
did not spend significantly more time in the target quadrant than other quadrants. (B)
Only the vehicle group displayed a significant probe trial as measured by annulus
crossings. Data are expressed as the mean ± SEM. * indicates p<.05. Vehicle: n=7;
ryanodine: n=7; thapsigargin: n=8.

Protein Level Analyses
The most pathologically relevant proteins to AD are Aβ and tau, especially oAβ
and ptau. To determine if inducing calcium dysregulation in the brain produced any
change in AD-related proteins, we performed SDS/PAGE to examine levels of oAβ and
ptau. When hippocampal tissue was examined for oAβ, it was discovered that
thapsigargin produced a significant increase in the protein levels of the 18mer (18 Aβ
monomers) versus vehicle (F2,22 = 4.303, p<.05; Tukey post-hocs revealed that
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thapsigargin significantly increased 18mer levels compared to vehicle, p<.05; see figure
6).
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Figure 6. Oligomeric Aβ protein levels in hippocampus from experiment 1 (n=4). (A)
Representative image of a membrane probed for oAβ (green) and β-actin (red). Arrows
indicate specific oligomers or β-actin. (B) Thapsigargin significantly increased 18mer
levels in the hippocampus compared to vehicle. Data are expressed as the mean ± SEM. *
indicates p<.05.

Although thapsigargin produced an overall increase in several species of oAβ, the
small group size (n=4) and large variability prohibited any other significant findings.
Table 2 summarizes the non-significant findings with the other oligomers from the
hippocampus.
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Table 2.
Western blot data from hippocampus in experiment 1 of Aβ oligomers with β-actin as a
loading control (n=4). Specific oligomers are listed with mean ± SEM levels for
ryanodine and thapsigargin, valued as proportion of control, which was set at 1. F and p
values are also listed for the one-way between groups ANOVAs performed to analyzed
the protein level differences among groups. Degrees of freedom were 2,22 for each
ANOVA. * indicates significant ANOVA (no between group differences).
Oligomer

Ryanodine

Thapsigargin

F value

p value

24mer

0.68 ± 0.17

0.58 ± 0.12

1.179

.326

20mer

0.84 ± 0.17

2.08 ± 0.77

2.178

.137

16mer

0.83 ± 0.43

1.51 ± 0.82

0.456

.639

12mer

0.84 ± 0.06

1.33 ± 0.21

3.129

.064

11mer

0.90 ± 0.14

1.13 ± 0.16

0.656

.529

10mer

0.65 ± 0.09

1.35 ± 0.30

3.462

.049*

9mer

0.64 ± 0.12

2.15 ± 0.80

2.887

.077

8mer

1.20 ± 0.31

1.61 ± 0.37

1.157

.333

Exploratory analyses were performed to assess if correlations existed between
individual subject MWM probe trial performance and levels of specific proteins.
Although there were no significant correlations for any specific oligomer when all groups
were examined, there was a strong negative correlation in the thapsigargin group between
probe trial performance and 24mer levels, indicating increased oAβ levels correlated with
poorer performance (F1,2 = 20.696, p<.05; see figure 7).
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Figure 7. Correlations between probe trial performance and hippocampal oAβ levels
from experiment 1 (n=4). The thapsigargin group’s probe trial time in target quadrant
difference score significantly correlated with 24mer oAβ levels, p<.05.

Tau phosphorylation was also investigated in the hippocampus following chronic
calcium dysregulation, specifically at the Serine 396 phosphorylation site. Both
ryanodine and thapsigargin produced a non-significant increase in tau phosphorylation
compared to vehicle (F2,22 = 0.764, p=.478; see figure 8). Similar to many of the oAβ
analyses, small group size (n=4) contributed to the lack of significant differences in this
pilot study. No correlations were found between ptau levels and probe performance.
CB-D28k levels in the hippocampus were not significantly different among
groups despite a large decrease following ryanodine or thapsigargin (F2,22 = 2.381,
p=.119; see figure 9). No correlations were discovered between probe trial performance
and CB-D28k levels in the hippocampus.
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Figure 8. Ptau protein levels in hippocampus from experiment 1 (n=4). (A)
Representative image of a membrane probed for tau phosphorylated at serine 396 (green)
and tau (red). Arrow indicates molecular weight of one of the tau bands. (B) No
significant differences were observed in ptau/tau levels despite modest increases
following chronic ryanodine or thapsigargin treatment. Data are expressed as the mean ±
SEM.

In the cortex, no significant differences were found in any of the oAβ species
among groups (see figure 10 for representative image and table 3 for a summary of the
data). Despite the lack of between-group differences in oAβ levels, strong negative
correlations were observed when individual groups were examined. In the ryanodine
group, a significant correlation was observed for the 24mer, similar to the hippocampus
for thapsigargin (F1,2 = 61.387, p<.05; see figure 11). Although non-significant, strong
negative correlations were observed in the thapsigargin group as well (10mer: R = .837,
p=.163; 9mer: R = .717, p=.283; 7mer: R = .813, p=.187).
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Figure 9. CB-D28k protein levels in hippocampus from experiment 1 (n=4). (A)
Representative image of a membrane probed for CB-D28k (red) and β-actin (green). (B)
No significant differences were observed in CB-D28k levels despite robust decreases
following chronic ryanodine or thapsigargin treatment. Data are expressed as the mean ±
SEM.
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Figure 10. Oligomeric Aβ protein levels in cortex from experiment 1 (n=4).
Representative image of a membrane probed for oAβ (green) and β-actin (red). Arrows
indicate specific oligomers or β-actin.
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Table 3.
Western blot data from cortex in experiment 1 of Aβ oligomers with β-actin as a loading
control (n=4). Specific oligomers are listed with mean ± SEM levels for ryanodine and
thapsigargin, valued as proportion of control, which was set at 1. F and p values are also
listed for the one-way between groups ANOVAs performed to analyzed the protein level
differences among groups. Degrees of freedom were 2,22 for each ANOVA.
Oligomer

Ryanodine

Thapsigargin

F value

p value

24mer

0.97 ± 0.09

0.93 ± 0.10

0.098

.907

20mer

1.06 ± 0.16

0.82 ± 0.16

0.432

.655

16mer

2.08 ± 0.79

2.92 ± 1.23

1.430

.261

12mer

1.08 ± 0.24

1.04 ± 0.14

0.044

.957

11mer

0.89 ± 0.11

0.85 ± 0.17

0.393

.680

10mer

0.81 ± 0.20

0.70 ± 0.15

0.970

.415

9mer

1.04 ± 0.17

1.06 ± 0.15

0.031

.970

8mer

1.17 ± 0.16

1.24 ± 0.22

0.549

.638

7mer

0.95 ± 0.13

0.92 ± 0.11

0.166

.848

Cortical ptau levels were also examined and similar to the hippocampus, a nonsignificant increase was observed following chronic ryanodine or thapsigargin
administration (F2,22 = 0.754, p=.482; see figure 12). No robust correlations were found
between probe trial performance and ptau levels in the cortex.
When membranes were probed for CB-D28k from the cortex, a similar but less
pronounced trend to the hippocampal levels emerged with no significant differences
among groups (F2,22 = 1.473, p=.251; see figure 13). No strong correlations were found
between probe performance and CB-D28k levels.
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Figure 11. Correlations between probe trial performance and cortical oAβ levels from
experiment 1 (n=4). The ryanodine group’s probe trial time in target quadrant score
significantly correlated with 24mer oAβ levels, p<.05.
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Figure 12. Ptau protein levels in cortex from experiment 1 (n=4). (A) Representative
image of a membrane probed for tau phosphorylated at serine 396 (green) and tau (red).
Arrow indicates molecular weight of one of the tau bands. (B) No significant differences
were observed in ptau/tau levels following chronic ryanodine or thapsigargin treatment.
Data are expressed as the mean ± SEM.

58

A"

Vehicle'

Thap'

Ryano' Vehicle' Thap'

Ryano'
β4ac5n''

Calbindin'D428k''

B"
Calbindin D-28k/Actin (Proportion to Control)

1.2

1

0.8

0.6

0.4

0.2

0

Vehicle'

Ryanodine'
Thapsigargin'
1

Figure 13. CB-D28k protein levels in cortex from experiment 1 (n=4). (A)
Representative image of a membrane probed for CB-D28k (red) and β-actin (green). (B)
No significant differences were observed in CB-D28k levels among groups. Data are
expressed as the mean ± SEM.

Experiment 2
Open Field Testing
When multiple dosages of ryanodine and thapsigargin were compared, there were
still no significant differences in the percent time subjects spent in the perimeter among
groups (F4,52 = 0.416, p=.797; see figure 14A). There were no treatment-induced effects
on locomotor activity as measured by total distance travelled (F4,52 = 1.138, p=.349; see
figure 14B).
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Figure 14. Open field testing in experiment 2. (A) No significant differences were found
among groups in the percent time spent in the perimeter or (B) the total distance
travelled. Data are expressed as the mean ± SEM. Vehicle: n=12; ryanodine at 1 µM:
n=11; ryanodine at 5 µM: n=10; thapsigargin at 20 µM: n=12; thapsigargin at 40 µM:
n=12.

Novel Object Recognition Testing
On the first day of NOR testing, there were no significant differences in the
amount of time spent with identical objects (object A) among groups (F4,52 = 1.278,
p=.291; see figure 15A). Because of the large N, no STM test could be performed in
experiment 2 within the 12 hour light cycle on day 1. On day 2, LTM was assessed with a
novel object (object B) being paired with object A (see figure 15B). Only the vehicle
group spent significantly more time with the novel object than chance (t11 = 2.256,
p<.05). Ryanodine at 1 or 5 µM and thapsigargin at 20 or 40 µM produced a learning and
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memory impairment (t10 = 0.357, p=728, t9 = 0.760, p=.467, t11 = 1.563, p=.146, and t11 =
-0.233, p=0.820, respectively).
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Figure 15. NOR testing in experiment 2. (A) No significant differences among groups
were found in the total time spent investigating the original objects (object A). (B) Only
vehicle animals displayed a significant preference for the novel object. Both doses of
ryanodine and thapsigargin produced a deficit, p>.05. Data are expressed as the mean ±
SEM. * indicates p<.05. Vehicle: n=12; ryanodine at 1 µM: n=11; ryanodine at 5 µM:
n=10; thapsigargin at 20 µM: n=12; thapsigargin at 40 µM: n=12.

Morris Water Maze Testing
Vehicle-treated subjects only required four days to reach the criterion latency in
experiment 2, for which there was a significant main effect of days (F3,633 = 139.686,
p<.01). There was no significant main effect of treatment for latency (F4,211 = 0.368,
p=.831; see figure 16A), speed of swimming (F4,210 = 1.033, p=.391; see figure 16B), or
thigmotaxis (F4,210 = 1.370, p=.246; see figure 16C).
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Figure 16. MWM testing in experiment 2. No differences were observed in latency to
reach the hidden platform (A), speed of swimming (B), or thigmotaxis (C) among groups.
Data are expressed as the mean ± SEM. Vehicle: n=11; ryanodine at 1 µM: n=10;
ryanodine at 5 µM: n=10; thapsigargin at 20 µM: n=12; thapsigargin at 40 µM: n=11.

A probe trial was conducted twenty-four hours later to assess spatial learning and
memory and no deficits were observed within any group in the percent time spent in the
target quadrant versus non-target quadrants (vehicle: F3,40 = 19.697, p<.01; Tukey posthocs target vs. non-target, p<.01 for all; ryanodine at 1 µM: F3,36 = 9.698, p<.01; Tukey
post-hocs target vs. adjacent left and adjacent right, p<.01, and target vs. opposite, p<.05;
ryanodine at 5 µM: F3,36 = 14.783, p<.01; Tukey post-hocs target vs. non-target, p<.01 for
all; thapsigargin at 20 µM: F3,44 = 5.654, p<.01; Tukey post-hocs target vs. adjacent left

62

and opposite, p<.01, and target vs. adjacent right, p<.05; thapsigargin at 40 µM: F3,40 =
15.972, p<.01; Tukey post-hocs target vs. non-target, p<.01 for all; see figure 17A).
When annulus crossings were examined, deficits were observed in the 5 µM
ryanodine group and the 20 µM thapsigargin group (ryanodine at 5 µM: F3,36 = 4.898,
p<.01; Tukey post-hocs target vs. adjacent right and opposite, p<.05, but target vs.
adjacent left, p=.198; thapsigargin at 20 µM: F3,44 = 4.272, p<.05; Tukey post-hocs target
vs. adjacent left, p<.01, but target vs. opposite and adjacent right, p=.108; see figure
17B). The other three groups each displayed significant annulus crossings during the
probe trial (vehicle: F3,40 = 4.821, p<.01; Tukey post-hocs target vs. non-target, p<.05 for
all; ryanodine at 1 µM: F3,36 = 11.242, p<.01; Tukey post-hocs target vs. non-target,
p<.01 for all; thapsigargin at 40 µM: F3,40 = 12.293, p<.01; Tukey post-hocs target vs.
non-target, p<.01 for all; see figure 17B).
Following the probe trial, animals underwent one day of visible training to
investigate any sensory or motor dysfunction. Similar to hidden training, no significant
differences were observed among groups in latency to find the visible platform (F4,207 =
0.528, p=.716; figure 16A), speed of swimming (F4,207 = 1.031, p=.392; figure 16B), or
thigmotaxis (F4,207 = 1.292, p=.274; figure 16C).
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Figure 17. MWM probe trial performance in experiment 2. (A) All groups spent
significantly more time in the target quadrant than the other three quadrants. (B)
Ryanodine at 5 µM and thapsigargin at 20 µM each impaired probe trial performance as
measured by annulus crossings. Data are expressed as the mean ± SEM. * indicates
p<.05. Vehicle: n=11; ryanodine at 1 µM: n=10; ryanodine at 5 µM: n=10; thapsigargin at
20 µM: n=12; thapsigargin at 40 µM: n=11.

Protein Level Analyses
Hippocampal tissue from rats in experiment 2 was probed for oAβ or ptau,
consistent with experiment 1. No significant differences were found in any of the oAβ
species among groups following chronic ryanodine or thapsigargin, contrary to
experiment 1 (see figure 18 and table 4 for representative images and comprehensive
results, respectively). Correlational analyses were performed for all subjects as well as for
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individual groups to investigate the relationship between probe trial performance and
oAβ levels. The only strong correlations were discovered in the 40 µM thapsigargin
group, suggesting poor probe trial performance in this group was related to increased oAβ
levels, although none reached significance (10mer: R = .752, p=.143; 9mer: R = .724,
p=.167; 8mer: R = .765, p=.132; 7mer: R = .652, p=.233).

Vehicle' Ry'1μM' Ry'5μM' Thap'20μM' Thap'40μM'
24mer'
20mer'

β7ac8n'
7mer'

Figure 18. Oligomeric Aβ protein levels in hippocampus from experiment 2 (n=5).
Representative image of a membrane probed for oAβ (green) and β-actin (red). Arrows
indicate specific oligomers or β-actin. No significant differences were observed in any
oAβ species among groups.

Tau phosphorylation was also examined in the hippocampus in experiment 2.
Although the lower dosage of ryanodine produced an increase in ptau, no significant
differences were observed among groups (F4,48 = 1.809, p=.142; see figure 19).
Interestingly, a strong negative correlation was observed in the 40 µM thapsigargin group
between probe performance and ptau levels, but it did not reach significance (R = .704,
p=.185).
Similar to the other proteins, no significant differences were observed among
groups in CB-D28k levels in the hippocampus (F4,47 = 3.041, p<.05; Tukey post-hocs did
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not reveal any significant differences among groups, p>.05; see figure 20). Based on the
lack of MWM deficits and the minimal differences observed in protein levels, no further
assays were conducted in experiment 2 to conserve resources.

Table 4.
Western blot data from experiment 2 of Aβ oligomers with β-actin as a loading control
(n=5). Specific oligomers are listed with mean ± SEM levels for each group, valued as
proportion of control, which was set at 1. F and p values are also listed for the one-way
between groups ANOVAs performed to analyzed the protein level differences among
groups. Degrees of freedom were 4,47 for each ANOVA.
Oligomer

Ryan 1µM

Ryan 5µM

Thap 20µM

Thap 40µM

F value

p value

24mer

1.08 ± 0.09 0.99 ± 0.08 1.04 ± 0.10 1.00 ± 0.05

0.265

.899

20mer

1.42 ± 0.17 1.13 ± 0.09 1.43 ± 0.23 1.24 ± 0.17

1.583

.194

16mer

1.17 ± 0.21 0.89 ± 0.11 1.01 ± 0.15 1.08 ± 0.12

0.348

.844

12mer

1.33 ± 0.30 1.04 ± 0.21 1.27 ± 0.31 1.23 ± 0.34

0.328

.858

10mer

1.08 ± 0.13 1.01 ± 0.16 1.07 ± 0.12 1.06 ± 0.10

0.108

.979

9mer

1.09 ± 0.21 0.78 ± 0.10 1.22 ± 0.29 1.22 ± 0.23

0.877

.485

8mer

1.07 ± 0.16 1.07 ± 0.10 1.21 ± 0.14 1.02 ± 0.12

0.511

.728

7mer

1.28 ± 0.19 1.05 ± 0.20 1.06 ± 0.19 1.57 ± 0.15

1.880

.130

Experiment 3
Effects of LPS on Temperature and Weight
Temperatures and weights were recorded immediately prior to and for three days
after the one-time administration of LPS. These measures were analyzed by group and by
LPS versus saline treatments. At baseline, no significant differences were observed in
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temperature by treatment (LPS vs. saline; F1,35 = 0.758, p=.390) or by group (vehicle,
LPS, thapsigargin, and Thap+LPS; F3,33 = 0.245, p=.865). Temperature was then
recorded at 24, 48, and 72 hours post-injection to assess whether LPS produced fever. As
figure 21A indicates, repeated measures ANOVA revealed that LPS produced a robust
increase in temperature across days (F2,70 = 7.348, p<.01) and versus saline (F1,35 =
24.675, p<.01). When examined by group, the data were similar across days (F2,70 =
7.172, p<.01) and by group (F3,33 = 8.542, p<.05; Tukey post-hocs revealed that both the
LPS and Thap+LPS groups displayed significantly increased temperatures compared to
vehicle, p<.01 for LPS and p<.05 for Thap+LPS; see figure 21B).
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Figure 19. Ptau protein levels in hippocampus from experiment 2 (n=5). (A)
Representative image of a membrane probed for tau phosphorylated at serine 396 (green)
and tau (red). Yellow indicates overlapping molecular weights. Arrow indicates
molecular weight of one of the tau bands. (B) No significant differences were observed in
ptau/tau levels. Data are expressed as the mean ± SEM.
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At baseline, no differences in weight were found by treatment (F1,35 = 1.145,
p=.292) or by group (F3,33 = 1.319, p=.285). However, when weights were examined at
the same time points as temperature, LPS produced a significant decrease in weight
across days (F2,70 = 9.440, p<.01) and versus saline (F1,35 = 6.567, p<.05; see figure 22A).
When analyzed by group, data were similar across days (F2,70 = 9.001, p<.01) but no
differences were observed among groups (F3,33 = 2.976, p<.05; Tukey post-hocs did not
show any differences among groups; figure 22B).
These data demonstrated that LPS did induce an acute immune response as
indicated by the significant increase in body temperature and significant reduction in
weight. These effects were temporary as both temperature and weight levels were no
longer significant versus controls 72 hours following injection.
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Figure 20. CB-D28k protein levels in hippocampus from experiment 2 (n=5). (A)
Representative image of a membrane probed for CB-D28k (red) and β-actin (green). (B)
No significant differences were observed in CB-D28k levels among groups. Data are
expressed as the mean ± SEM.
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Figure 21. Temperature data at baseline and at multiple time points following LPS or
saline injections. (A) LPS injection significantly increased body temperature regardless
of group when compared to animals injected with saline, p<.01. (B) When compared to
vehicle, the LPS alone and Thap+LPS groups displayed significantly elevated
temperatures following LPS injection, p<.01 for LPS and p<.05 for Thap+LPS. Data are
expressed as the mean ± standard error of the mean (SEM). Vehicle: n=10; LPS: n=9;
thapsigargin: n=9; thap+LPS: n=9.

Open Field Testing
Neither LPS nor the combination of thapsigargin and LPS altered open field
performance from experiments 1 and 2. No differences were observed in the percent time
spent in the perimeter among groups (F3,32 = 0.278, p=.841; see figure 23A) nor in the
total distance travelled (F3,32 = 1.216, p=.320; see figure 23B). Collectively, these studies
suggest that none of the individual ligands administered, nor the combination of
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thapsigargin and LPS, produced anxiogenic effects or impaired gross locomotor abilities.
Therefore, any deficits observed in NOR or MWM tasks can be attributed to
hippocampally-mediated learning and memory impairments.
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Figure 22. Analysis of weights at baseline and at multiple time points following LPS or
saline injections. (A) LPS injection significantly decreased body weight regardless of
group when compared to animals injected with saline, p<.05. (B) No significant
differences were observed in weight across days when all groups were compared. Data
are expressed as the mean ± SEM. Vehicle: n=10; LPS: n=9; thapsigargin: n=9;
thap+LPS: n=9.
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Figure 23. Open field testing in experiment 3. (A) No significant differences were found
among groups in the percent time spent in the perimeter or (B) the total distance
travelled. Data are expressed as the mean ± SEM. Vehicle: n=10; LPS: n=9; thapsigargin:
n=8; thap+LPS: n=9.

Novel Object Recognition Testing
Similar to experiments 1 and 2, no differences in object exploration were
observed on day 1 among groups (F3,32 = 0.559, p=.646; see figure 24A). In the LTM test
on day 2 when a novel object was presented (see figure 24B), none of the groups
exhibited a significant preference for the novel object (vehicle: t9 = -0.815, p=.436; LPS:
t8 = 1.084, p=.310; thapsigargin: t7 = 2.036, p=.081; thap+LPS: t8 = 0.232, p=.822). The
lack of any group displaying preference for the novel object may be due to the advanced
age of the rats.
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Figure 24. NOR testing in experiment 3. (A) No significant differences among groups
were found in the total time spent investigating the original objects. (B) None of the
groups displayed a significant preference for the novel object compared to chance levels,
p>.05. Data are expressed as the mean ± SEM. Vehicle: n=10; LPS: n=9; thapsigargin:
n=8; thap+LPS: n=9.

Morris Water Maze Testing
In experiment 3, vehicle-treated animals needed six days to achieve the criterion
latency. There was a significant main effect of days (F5,700 = 83.882, p<.01) but no
significant main effect of treatment (F3,140 = 0.760, p=.518; see figure 25A). Similarly, no
differences among groups were observed in speed of swimming (F3,139 = 0.290, p=.832;
see figure 25B) or thigmotaxis (F3,139 = 0.305, p=.822; see figure 25C).
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Figure 25. MWM testing in experiment 3. No differences were observed in latency to
reach the hidden platform (A), speed of swimming (B), or thigmotaxis (C) among groups.
Data are expressed as the mean ± SEM. Vehicle: n=10; LPS: n=9; thapsigargin: n=8;
thap+LPS: n=9.

A probe trial was conducted twenty-four hours following achievement of latency
criterion (see figure 26). The combination of thapsigargin and LPS produced a subtle, but
significant impairment in probe trial performance as measured by percent time spent in
each quadrant (F3,32 = 5.679, p<.01; Tukey post-hocs target vs. opposite, p<.01, and
target vs. adjacent left, p<.05, but target vs. adjacent right, p=.053; figure 26A). The other
three groups displayed a selective search based on time spent in target compared to other
quadrants (vehicle: F3,36 = 20.580, p<.01; Tukey post-hocs target p<.01 vs. all other
quadrants; LPS: F3,32 = 7.010, p<.01; Tukey post-hocs target vs. adjacent left and right,
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p<.05, target vs. opposite, p<.01; thapsigargin: F3,28 = 11.113, p<.01; Tukey post-hocs
target p<.01 vs. all other quadrants; see figure 26A).
Annulus crossings data revealed that the LPS and thapsigargin groups each
displayed deficits (LPS: F3,32 = 2.629, p=.067; thapsigargin: F3,28 = 5.194, p<.01; Tukey
post-hocs target vs. adjacent left, p=.059, target vs. opposite, p<.05, and target vs.
adjacent right, p<.01; see figure 26B). Vehicle-treated rats crossed the previous platform
location significantly more often than non-target quadrants (F3,36 = 11.760, p<.01; Tukey
post-hocs target p<.01 vs. all other quadrants; figure 26B). Despite not displaying a
selective search based on percent time in quadrant, the group administered thapsigargin
and LPS did show significance based on annulus crossings (F3,32 = 7.435, p<.01; Tukey
post-hocs target vs. adjacent left and right, p<.05, target vs. opposite, p<.01; figure 26B).
Following the probe trial, two days of visible platform training were performed to
assess visuomotor abilities. Similar to hidden platform training, no significant differences
were found among groups in latency (F3,140 = 0.456, p=713; see figure 25A), speed of
swimming (F3,140 = 2.835, p<.05; Tukey post-hocs showed that p>.05 for each group vs.
vehicle; see figure 25B), or thigmotaxis (F3,140 = 0.423, p=.737; see figure 25C).
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Figure 26. MWM probe trial performance in experiment 3. (A) The combination of
thapsigargin and LPS produced a deficit in probe trial percent time in target versus nontarget quadrants. (B) LPS and thapsigargin each impaired probe trial performance as
measured by annulus crossings. Data are expressed as the mean ± SEM. * indicates
p<.05. Vehicle: n=10; LPS: n=9; thapsigargin: n=8; thap+LPS: n=9.

Protein Level Analyses
Hippocampal tissue from rats in experiment 3 was probed for oAβ, similar to the
previous studies. Following the administration of LPS and/or thapsigargin, there was a
significant reduction in the 18mer in the thap+LPS group (F3,47 = 3.879, p<.05; Tukey
post-hocs revealed that the combination of thapsigargin and LPS significantly reduced
18mer Aβ levels compared to vehicle, p<.05; see figure 27). No significant differences
were observed in any other oligomeric species; these data are summarized in table 5.
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Figure 27. Oligomeric Aβ protein levels in hippocampus from experiment 3 (n=6). (A)
Representative image of a membrane probed for oAβ (green) and β-actin (red). Arrows
indicate specific oligomers or β-actin. (B) Thapsigargin plus LPS significantly decreased
18mer levels in the hippocampus compared to vehicle. Data are expressed as the mean ±
SEM. * indicates p<.05.

Correlational analyses were performed with hippocampal oAβ levels and probe
trial performance. Significant negative correlations were discovered when all groups
were examined versus vehicle at the 10mer (F1,16 = 4.565, p<.05; see figure 28A) and
8mer (F1,16 = 6.567, p<.05; see figure 28B) oligomers while non-significant correlations
were found in others (16mer: R = .451, p=.060; 11mer: R = .346, p=.159; 9mer: R = .324,
p=.190; 7mer: R = .389, p=.111). When individual groups were examined, significant
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correlations were observed in the thap+LPS group in 11mer levels (F1,4 = 16.182, p<.05;
see figure 29A) and 7mer levels (F1,4 = 8,526, p<.05; see figure 29B). Strong, but nonsignificant negative correlations were also found in this group (10mer: R = .737, p=.094;
9mer: R = .770, p=.073; 8mer: R = .749, p=.086) and the thapsigargin group (16mer: R =
.648, p=.164; 8mer: R = .644; p=.168).

Table 5.
Western blot data from hippocampus in experiment 3 of Aβ oligomers with β-actin as a
loading control (n=6). Specific oligomers are listed with mean ± SEM levels for each
group, valued as proportion of control, which was set at 1. F and p values are also listed
for the one-way between groups ANOVAs performed to analyzed the protein level
differences among groups. Degrees of freedom were 3,47 for each ANOVA.
Oligomer

LPS

Thapsigargin

Thap+LPS

F value

p value

24mer

0.90 ± 0.08

0.78 ± 0.09

0.87 ± 0.10

1.111

.354

20mer

0.99 ± 0.12

0.87 ± 0.14

0.93 ± 0.10

0.340

.796

19mer

1.82 ± 0.67

1.14 ± 0.24

1.39 ± 0.58

0.547

.652

16mer

1.11 ± 0.20

1.01 ± 0.18

1.14 ± 0.18

0.162

.921

12mer

1.19 ± 0.16

1.12 ± 0.23

0.71 ± 0.08

2.227

.098

11mer

0.89 ± 0.05

0.80 ± 0.08

0.70 ± 0.10

2.668

.058

10mer

0.93 ± 0.11

0.88 ± 0.10

0.94 ± 0.18

0.161

.922

9mer

0.93 ± 0.10

0.81 ± 0.18

0.67 ± 0.11

1.207

.318

8mer

0.90 ± 0.10

0.91 ± 0.09

0.92 ± 0.09

0.280

.839

7mer

0.96 ± 0.09

0.89 ± 0.09

0.91 ± 0.08

0.366

.778
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Figure 28. Correlations between probe trial performance and hippocampal oAβ levels
from experiment 3 (n=6). When all subjects were examined, significant correlations were
found between probe trial time in target quadrant and 10mer oAβ levels (A) and 8mer
levels (B), p<.05.

When ptau levels were examined in the hippocampus, no significant differences
were found among groups despite a modest increase in the thap+LPS group (F3,44 =
1.144, p=.342; see figure 30). No correlations were found between probe trial
performance and levels of ptau in the hippocampus.
To confirm any differences in ptau were not due altered levels of endogenous tau
proteins, levels of tau were also examined in the hippocampus. As expected, no
differences were observed among the groups in tau levels (F3,44 = 0.297, p=.827; see
figure 31).
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Figure 29. Correlations between thap+LPS group probe trial performance and
hippocampal oAβ levels from experiment 3 (n=6). In the thap+LPS group, significant
correlations were found between probe trial time in target quadrant and 11mer oAβ levels
(A) and 7mer levels (B), p<.05.
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Figure 30. Ptau protein levels in hippocampus from experiment 3 (n=6). (A)
Representative image of a membrane probed for tau phosphorylated at serine 396 (green)
and β-actin (red). (B) No significant differences were observed in ptau levels among
groups. Data are expressed as the mean ± SEM.

79

A"

Vehicle'

LPS'

Thap'

Thap+LPS'

62'kDa'

β4ac5n'

B" 1.6
Tau/Actin (Proportion to Control)

1.4
1.2
1
0.8
0.6
0.4
0.2
0

Vehicle'

LPS'

1

Thap'

Thap+LPS'

Figure 31. Tau protein levels in hippocampus from experiment 3 (n=6). (A)
Representative image of a membrane probed for tau (red) and β-actin (green). Arrow
indicates molecular weight of one of the tau bands. (B) No significant differences were
observed in tau levels among groups. Data are expressed as the mean ± SEM.

Although no significant differences were observed among groups in CB-D28k
levels in the hippocampus (F3,44 = 2.452, p=.076; see figure 32), there was likely a
meaningful reduction in the LPS and thapsigargin groups. No correlations were found in
the hippocampus between probe performance and CB-D28k levels.
When protein levels of oAβ were examined in the cortex, a significant increase
was observed in 8mer levels following chronic thapsigargin treatment (F3,44 = 4.506,
p<.01; Tukey post-hocs revealed that thapsigargin produced a significant increase versus
vehicle, p<.01; see figure 33). No differences were found in the other oligomeric species;
these data are summarized in table 6. No strong correlations were discovered between
probe trial performance and oAβ protein levels in the cortex.
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Figure 32. CB-D28k protein levels in hippocampus from experiment 3 (n=6). (A)
Representative image of a membrane probed for CB-D28k (red) and β-actin (green). (B)
No significant differences were observed in CB-D28k levels among groups. Data are
expressed as the mean ± SEM.
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Figure 33. Oligomeric Aβ protein levels in cortex from experiment 3 (n=6). (A)
Representative image of a membrane probed for oAβ (green) and β-actin (red). Arrows
indicate specific oligomers or β-actin. (B) Thapsigargin significantly increased 8mer
levels in the cortex compared to vehicle. Data are expressed as the mean ± SEM. *
indicates p<.01.
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Table 6.
Western blot data from cortex in experiment 3 of Aβ oligomers with β-actin as a loading
control (n=6). Specific oligomers are listed with mean ± SEM levels for each group,
valued as proportion of control, which was set at 1. F and p values are also listed for the
one-way between groups ANOVAs performed to analyzed the protein level differences
among groups. Degrees of freedom were 3,44 for each ANOVA.
Oligomer

LPS

Thapsigargin

Thap+LPS

F value

p value

24mer

1.18 ± 0.13

0.95 ± 0.09

1.06 ± 0.09

1.139

.344

20mer

1.08 ± 0.08

0.82 ± 0.09

1.00 ± 0.14

0.762

.521

18mer

1.49 ± 0.25

1.26 ± 0.25

1.31 ± 0.32

0.701

.557

12mer

1.37 ± 0.33

1.20 ± 0.22

0.99 ± 0.17

0.711

.551

11mer

1.15 ± 0.09

0.96 ± 0.05

0.94 ± 0.06

2.156

.107

7mer

1.03 ± 0.11

0.86 ± 0.03

0.92 ± 0.06

1.393

.258

Tau phosphorylation was investigated in the cortex as well and a robust increase
was observed in the thap+LPS group, although it failed to reach significance, p=.057
(F3,44 = 5.527, p<.01; Tukey post-hocs did not reveal any significant differences among
groups; see figure 34). A moderate negative correlation was found in the thap+LPS group
between probe trial performance and ptau levels (R = .596) but it was not significant
(p=.212).
CB-D28k levels in the cortex did not significantly differ among groups but there
was a slight reduction in the thapsigargin group (F3,44 = 0.547, p=.653; see figure 35).
There was however a significant positive correlation in the thap+LPS group between CBD28k levels and probe trial performance (F1,4 = 27.021, p<.01; see figure 36).
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Figure 34. Ptau protein levels in cortex from experiment 3 (n=6). (A) Representative
image of a membrane probed for tau phosphorylated at serine 396 (green) and β-actin
(red). (B) No significant differences were observed in ptau levels among groups despite a
large increase in the thap+LPS group (p=.057). Data are expressed as the mean ± SEM.
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Figure 35. CB-D28k protein levels in cortex from experiment 3 (n=6). (A)
Representative image of a membrane probed for CB-D28k (red) and β-actin (green). (B)
No significant differences were observed in CB-D28k levels among groups. Data are
expressed as the mean ± SEM.
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Figure 36. Correlations between thap+LPS group probe trial performance and cortical
CB-D28k levels from experiment 3 (n=6). In the thap+LPS group, a significant
correlation was found between probe trial time in target quadrant and CB-D28k levels in
the cortex, p<.01.
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CHAPTER 5
DISCUSSION
The above series of experiments was designed to evaluate the hypothesis that
disrupting intracellular calcium homeostasis would be sufficient to elicit behavioral and
neurological manifestations of AD. In order to investigate this hypothesis, compounds
that perturb ER calcium regulation were chronically administered to rats, which were
tested in multiple learning and memory paradigms. Brain neurochemistry was then
examined in the hippocampus and cortex for protein markers consistently altered in AD.
The data from these studies suggest calcium dysregulation disrupts aspects of
hippocampal-dependent learning and memory, while producing variable changes in ADrelated proteins in the brain.

Experiment 1
A pilot study was initially conducted with a relatively small group size (n=8) to
assess if chronically altering intracellular calcium regulation produced AD-like changes
in behavior or neurochemistry. The open field, NOR, and MWM tasks were conducted
four weeks following implantation of osmotic min-pumps, which steadily released either
vehicle, ryanodine (250 nM) or thapsigargin (10 µM) into the right lateral ventricle. Open
field data indicated that neither ryanodine nor thapsigargin produced anxiogenic effects
or affected locomotor activity. Learning and memory was first examined in NOR testing,
which included a STM and LTM component. Deficits were observed in the thapsigargin
group in both STM and LTM for novel object preference, indicating a learning
impairment in this group. No deficits were found in the ryanodine group. Surprisingly,
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vehicle animals also displayed an impairment in the LTM test, data which could reflect
the inconsistency sometimes observed in rodent novelty-seeking behavior.
Thapsigargin impaired MWM acquisition, as measured by latency to the hidden
platform, and probe trial annulus crossings. These data reveal a robust cognitive deficit in
this group, which is consistent with the deficits observed in NOR. Ryanodine also
produced a probe trial impairment, both in percent time spent in the target quadrant and
annulus crossings, indicating a spatial learning and memory deficit. Overall, these data
suggest that altering ER calcium regulation with ryanodine or thapsigargin is sufficient to
disrupt hippocampal-dependent learning and memory, similar to the deficits observed in
AD patients.
Following the completion of behavioral testing, brains were dissected out and
specific brain regions were homogenized to examine protein levels. Levels of oAβ, a
pathogenic contributor in AD (Lesné et al., 2006; Walsh et al., 2002), were significantly
increased in the hippocampus following thapsigargin treatment at the 72 kDa band, which
likely corresponds to an 18mer. Ryanodine produced a similar elevation in 18mer levels
but it did not reach significance. Although thapsigargin increased levels of several other
oligomers in the hippocampus, the small group size and large variability may have
influenced the lack of significant results. Interestingly, a significant negative correlation
was observed in the thapsigargin group between probe trial performance and 24mer oAβ
levels. This correlation indicates that larger levels of 24mers were related to poorer probe
performance, findings that reflect the correlations observed in AD mouse models (Lesné
et al., 2006) and AD patients (Santos et al., 2012) between cognitive deficits and oAβ. In
the cortex, no significant differences were observed in any of the oAβs suggesting the
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thapsigargin-induced increase is region-specific. There was however a significant
negative correlation in the ryanodine group between probe performance and 24mer
levels, similar to that observed in the hippocampus in the thapsigargin group.
Collectively, these data suggest that perturbing calcium regulation does alter levels of
oAβ, but not in a manner entirely consistent with AD or mutant mouse models of the
disease.
When the degree of tau phosphorylated at Serine 396 was examined in the
hippocampus and cortex, no significant changes were observed following chronic
ryanodine or thapsigargin treatment. Although small increases were found in each brain
region, these did not mirror the large tau phosphorylation seen in AD or other studies that
altered calcium regulation (Fu et al., 2010).
CB-D28k levels were not significantly changed following chronic ryanodine or
thapsigargin infusion, despite the large reduction observed in the ryanodine group in the
hippocampus (~60% reduction). Although the lack of significance limits the
interpretations that can be made, it is interesting to note that CB-D28k levels are
consistently reduced in AD brains (Iacopino & Christakos, 1990; Riascos et al., 2011)
and mouse models of AD (Palop et al., 2003). It is difficult to extrapolate the findings
from the current study to AD, but the alterations observed in CB-D28k levels are likely
physiologically relevant despite their lack of significance. Furthermore, these findings
suggest that the compounds administered did have a direct effect on calcium signaling as
evidenced by the changes in CB-D28k, an important calcium-binding protein.
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Experiment 2
Because the results of the pilot study (experiment 1) indicated this approach may
have promise to investigate mechanisms of AD, experiment 2 was designed to examine
the effects of calcium dysregulation on a larger scale. The group size was increased to an
n of 12 and dosages of ryanodine or thapsigargin were increased in order to produce more
robust and uniform effects. An identical timeline as experiment 1 was performed for
surgery, behavioral studies, and tissue collection and all methods conducted were
identical to experiment 1. Open field data were similar to experiment 1, with no
differences among groups, indicating that increasing the dose of these ligands did not
alter locomotion or produce an anxiety phenotype. When NOR testing was performed, no
differences were observed among groups in total time spent exploring the identical
objects on Day 1, suggesting none of the drugs induced any neophobic effects. On Day 2,
only vehicle subjects displayed a significant preference for the novel object compared to
chance levels, indicating each of the treatments administered impaired NOR learning.
MWM testing commenced the following week and no differences were observed
among groups in the acquisition phase of the task. Surprisingly, none of the groups
displayed impairment on the probe trial as measured by percent time in quadrant. Subtle
deficits were observed following chronic ryanodine at 5 µM or thapsigargin at 20 µM in
the number of annulus crossings; however, these differences were neither as robust as
anticipated nor reflective of AD-like impairments.
To assess if the drugs altered protein levels of AD-related markers, SDS/PAGE
was initially performed on hippocampal samples. Interestingly, no significant differences
were found in any of the targets examined (oAβ, ptau, or CB-D28k) among groups,
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suggesting that the increased dosages did not enlarge nor even replicate the changes in
experiment 1. Despite the lack of any significant differences among groups, CB-D28k
levels displayed significant positive correlations with several oAβ species, including
7mers (R = .546, p<.05), 9mers (R = .516, p<.05), 10mers (R = .514, p<.05), and 16mers
(R = .784, p<.01) (data not shown). It is unclear why there would be a positive
relationship between CB-D28k and oAβ, as most studies imply a neuroprotective role for
CB-D28k (Iacopino et al., 1992). It is also plausible that the correlation does not
represent a direct causal relationship between the expression of these proteins.
The possibility exists that increasing the dose of each ligand forced neurons to
compensate for the alterations in either RyR or SERCA function within the ER. For
example, changes in the physiological functioning of the ER can produce ER stress as
mentioned above (Unterberger et al., 2006). In an attempt to counteract the stress, cells
may initiate the UPR to increase protein folding capacity and restore functioning to a
homeostatic level (Kaufman, 1999).
Alternatively, if the increased dosages of these drugs resulted in cytotoxic levels
of intracellular calcium, direct changes in calcium-related physiology may have occurred,
such as an upregulation of SERCA pumps, downregulation of RYRs, or a change in any
of the other numerous proteins that regulate calcium levels (Wernyj et al., 1999). Future
studies may be able to illuminate the mechanisms responsible for the lack of cognitive
deficits and protein-level differences in experiment 2. However, because no robust
behavioral or neurological changes were found in this experiment, no further assays were
conducted in order to conserve resources.
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Experiment 3
Because increasing the drug dose and group size in experiment 2 did not produce
the AD phenotype desired, an alternative approach was employed in an attempt to more
accurately model what may be occurring in AD. Specifically, we administered LPS
coupled with chronic calcium dysregulation via thapsigargin to evaluate if inducing an
acute neuroimmune response would be sufficient to produce AD-like behavior and
pathology. Additionally, we employed aged rats (10-12 months old) because they likely
have less capacity to compensate for any neurotoxic insults and more closely match an atrisk AD population. As mentioned above (see page 35), because it could not be
determined exactly what concentration of thapsigargin was in the osmotic pumps, the
results from this experiment are difficult to generalize and must be interpreted with care.
Immediately following the acute LPS injection, which was administered two
weeks after surgery, temperatures and weights were recorded to determine if LPS
produced an immune response. As expected, LPS significantly increased body
temperature and significantly decreased weight for up to 48 hours following the injection.
Levels returned to baseline by 72 hours post-injection. Based on these data, it was evident
an immune response was mounted which previous work has shown leads to prolonged
neuroinflammation, cytokine release, and microglial activation (Qin et al., 2007).
Behavioral testing commenced three weeks later with open field and NOR.
No anxiety phenotype or changes in locomotion were observed during open field
testing in experiment 3, consistent with the previous studies. During NOR testing, no
differences were observed among groups in the time spent exploring objects on Day 1.
Surprisingly, no groups displayed a significant preference for the novel object the
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following day when it was presented with the familiar object. The vehicle group
performed especially poorly, suggesting aged rats may encounter more difficulty with the
task (de Lima et al., 2005) or perhaps exhibit less motivation for novelty-seeking
behavior than younger animals. Unfortunately, the meaningfulness of the deficits
observed in the other groups is diminished by the lack of significance in the control
group. Therefore, the impairment in the vehicle group limits the interpretations that can
be made about the drug-induced deficits.
During the MWM acquisition phase, no significant differences were observed
among groups, suggesting all groups were able to similarly locate the platform. The
thap+LPS group did display a deficit in the probe trial as measured by percent time in
target quadrant, but not annulus crossings. Interestingly, although neither LPS nor
thapsigargin impaired percent time in quadrant, each group showed a deficit in annulus
crossings. Therefore, each treatment did manifest a learning and memory impairment in
one aspect of the probe trial. However, the cognitive deficits exhibited by these groups
did not come close to mirroring those observed in AD, suggesting the combination of
thapsigargin and LPS was not sufficient to produce AD-like behavioral changes. If the
dosage of thapsigargin had been 25 µM, as intended, it is possible more pronounced
impairments would have been observed in these aged rats, similar to experiment 1 which
employed a lower dose of 10 µM.
When protein levels were examined in the hippocampus, the thap+LPS group was
found to have significantly decreased 18mer oAβ levels compared to vehicle. This result
is in contrast to the data from experiment 1 showing that thapsigargin significantly
increased 18mer levels in the hippocampus. In experiment 3, thapsigargin did not
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produce any significant difference, whereas the combination of thap+LPS did
significantly decrease 18mer levels. These data collectively may suggest that inducing an
acute inflammatory response could reduce oAβ levels and potentially be beneficial.
However, because thapsigargin in experiment 3 did not replicate the effects observed in
experiment 1, further experiments would be necessary to make any definitive
conclusions. If the thapsigargin dose had been 25 µM, a change in oAβ levels more
similar to experiment 1 may have been observed and the thap+LPS group reduction may
not have been seen.
Although no other significant differences were observed in oAβ levels, interesting
correlations emerged between probe trial performance and smaller size oligomers. When
all groups were examined, significant negative correlations were found between probe
trial time in quadrant scores and either 10mer or 8mer levels. These data indicate that
more impaired probe performance was related to larger levels of oAβ. Whether there is a
direct causal relationship between cognitive performance and oAβ is unclear from the
current data, although previous studies have shown oAβ can directly induce learning and
memory deficits (Cleary et al., 2005; Lesné et al., 2006). Significant negative correlations
were further observed in the thap+LPS group between probe performance and either
11mer or 7mer levels. These findings reinforce the notion that oAβ may contribute to
cognitive deficits.
In the cortex, thapsigargin produced a significant increase in 8mer oAβ levels
compared to vehicle, a change that was not observed when LPS was administered during
chronic thapsigargin treatment (thap+LPS group). LPS binds to CD14 proteins and
activates the toll-like receptor 4 (TLR4), which initiates an important signaling cascade
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for the immune response (Kurt-Jones et al., 2000; Xia et al., 2006). In a transgenic mouse
model of AD with the TLR4 gene knocked out, amyloid pathology was aggravated
(Tahada et al., 2006), suggesting the immune response may be beneficial in AD. In the
current study, it is possible that the administration of LPS mitigated the increase in oAβ
levels observed in the thapsigargin group. This interpretation is supported by previous
work demonstrating that LPS enhances the phagocytosis of exogenous Aβ (Liu et al.,
2005).
Tau phosphorylation was quantified in two different ways in experiment 3. In the
hippocampus, ptau levels were compared to β-actin while tau levels were separately
compared to β-actin; no significant differences were observed among groups in either
comparison. This alternative approach to quantify ptau and tau was performed to be
consistent with the majority of the literature, which reports levels of ptau and tau
independent of each other. However, it is likely the lack of direct ptau/tau comparisons is
a byproduct of technique limitations rather than a methodological consideration. The
Odyssey fluorescent imaging system used in the current experiments permitted the
detection of proteins of similar molecular weights; other imaging approaches typically
have more difficulty with this type of detection. Regardless of the approach, none of the
ligands administered altered tau phosphorylation in the hippocampus. Furthermore, it is
unlikely the thapsigargin dosage affected ptau levels; none of the experiments indicated
any change in the levels of this protein following any dose of thapsigargin.
In the cortex, there were once again no significant differences among groups in
ptau/tau levels, despite a likely meaningful 40% increase in the thap+LPS group
(p=.057). Thapsigargin has been previously demonstrated to significantly enhance tau
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phosphorylation following acute intracerebral infusion into the lateral ventricle (Fu et al.,
2010). LPS has been shown to exacerbate tau pathology in a transgenic model of AD
(Lee et al., 2010), suggesting the LPS injection may have potentiated any thapsigargininduced effects on tau phosphorylation in the current study.
Consistent with experiment 1, thapsigargin produced a non-significant decrease in
CB-D28k levels in the hippocampus (~40%), suggesting that the drug likely altered
calcium regulation. Interestingly, LPS produced a similar decrease in the hippocampus, a
finding consistent with previous research showing decreased CB-D28k expression
following administration of tumor necrosis factor-α (TNF-α) (Parkash et al., 2005), a
proinflammatory cytokine whose production is increased by LPS (Nadeau & Rivest,
1999). Surprisingly, the combination of thapsigargin and LPS did not alter CB-D28k
levels in a similar fashion to either LPS or thapsigargin alone. Without performing further
assays to parse out the potential mechanism(s) responsible for these differences, it is
unclear why the CB-D28k levels may differ among these groups. Although these
differences are consistent with experiment 1, the possibility exists that a lower dosage of
thapsigargin in aged animals would have produced a more robust reduction in CB-D28k
levels.
Interestingly, there was a strong positive correlation between hippocampal CBD28k levels and 18mer oAβ levels in the thap+LPS group (R = .807, p=.052; data not
shown). This correlation raises the possibility that the significant decrease observed in
18mer levels in the thap+LPS group could be related to its levels of CB-D28k. Why the
increased presence of CB-D28k would be related to increased oAβ levels is unclear;
however it is interesting to note that this relationship between increased CB-D28k and
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oAβ was observed in the hippocampus in experiment 2 as well. Of course this possibility
can merely be speculated at this point without further data to support it.
Although no changes were observed in the cortex in CB-D28k levels among
groups, a significant positive correlation was found between probe performance and CBD28k levels in the thap+LPS group, indicating a greater degree of CB-D28k was related
to better performance. A significant negative correlation was found between CB-D28k
levels and ptau levels in the cortex when all groups were examined (R = .580, p<.05; data
not shown), suggesting the increased presence of CB-D28k reduced the amount of tau
phosphorylation. Once again these conclusions cannot be confirmed without the inclusion
of further testing and data collection. Furthermore, similar to the data from the
hippocampus and from experiment 2, significant positive correlations were found
between CB-D28k levels and oAβ levels among all groups for 7mers (R = .725, p<.01),
11mers (R = .556, p<.05), and 24mers (R = .590, p<.05). As mentioned above however,
the importance of these relationships is unclear, especially with minimal significant
differences observed in the between group protein level analyses.

Conclusions
The goal of the current series of experiments was to directly examine the
hypothesis that prolonged intracellular calcium dysregulation could lead to Alzheimer’slike changes in the brain and behavior. It is evident from the data reported above that at
least in a wild-type rodent model, this approach does not produce the robust cognitive
deficits or biochemical changes normally associated with AD. However, interesting and
novel information has still been obtained from these experiments. The data demonstrate
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that chronic ryanodine or thapsigargin infusion into the lateral ventricle impairs learning
and memory in multiple behavioral paradigms at multiple dosages and ages. These
studies also show that thapsigargin treatment is sufficient to elevate oAβ levels in
multiple brain regions at multiple dosages (see experiments 1 and 3). The considerable
amount of tau phosphorylation typically observed in AD patients and models of AD was
not observed in the current experiments, despite modest increases in various groups.
Furthermore, the decreased expression of CB-D28k observed, although consistent with
AD, never reached a level of statistical significance.
It is interesting to consider potential explanations for the alterations in CB-D28k
levels in these experiments. Intuitively, elevated cytosolic calcium concentration, as is
hypothesized to occur following chronic ryanodine or thapsigargin treatment, should lead
to increased levels of a calcium buffering protein in an effort to reduce any calciuminduced excitotoxicity or synaptic dysfunction. However, the opposite effect was
observed in the above studies. Interestingly, it has been shown that CB-D28k expression
is decreased following a calcium overload induced by either glutamate (Mao et al., 2010)
or status epilepticus in rats (Carter et al., 2008). CB-D28k levels may be reduced to
enhance calcium-dependent inactivation (CDI) of voltage-gated calcium entry, an
important mechanism to reduce net calcium influx following depolarization (Köhr &
Mody, 1991). In support of this hypothesis, low or absent CB-D28k expression from
Ammon’s horn sclerosis (AHS; Nagerl & Mody, 1998) or CB-D28k gene knockout
(Klapstein et al., 1998) leads to increased CDI and a corresponding decrease in calcium
load. It is possible the decreased CB-D28k levels observed following chronic ryanodine,
or to a lesser extent thapsigargin, serve a compensatory mechanism to enhance CDI and
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reduce intracellular calcium overload. Future experiments employing calcium imaging or
electrophysiological techniques may be able to test these hypotheses.
Overall, these experiments demonstrated that chronic calcium dysregulation is
likely related to AD pathophysiology; however, it is likely not the sole etiologic factor
that initiates AD pathology and symptoms. These data also indicated that although our
manipulations did affect behavior and neurochemistry to a certain extent, the deficits
observed in our studies were not consistent with other animal models of AD (Cleary et
al., 2005; Hsiao et al., 1996). It may be interesting to perform these experiments in
existing transgenic mouse models of AD, as they already exhibit robust AD pathology.
This approach would elucidate how calcium dysregulation interacts with amyloid and/or
tau pathology and perhaps advance our understanding of AD.
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